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1. Summary 
 
The glomerular filtration barrier is an efficient filtration system, which ensures proper 
function of the kidney by avoiding proteinuria. At the same time, this barrier is also the 
most vulnerable component of the kidney. The podocyte, a terminal differentiated cell, is 
the key player in maintaining integrity. Most of the kidney diseases initiate from injuries of 
the podocytes, which lead to effacement with slit diaphragm disruption, followed 
ultimately by cell detachment and loss. Such a lesion can only be detected by electron 
microscopy.  
The goal of the present work was to identify early marker(s) of podocyte injury, which are 
uniquely expressed in these cells and are very sensitive to stress or any other type of 
insults. With such marker at hand, early evaluation of podocyte injury and disease 
progression to the entire nephron can be explored. 
By applying gene expression profile analysis on laser capture microdissected glomeruli two 
novel podocytes markers, Semaphorin-3G (Sema3G) and Cystatin C (CYTC) could be 
identified. Their specific expression in podocytes was further confirmed by the use of in 
situ hybridization and immunohistochemistry on rat kidney tissue sections. 
In a next step, modulation of Sema3G and CYTC was further assessed in models of podocyte 
injury (functional and structural impairment and drug-induced toxicity models). 
Sema3G is a very sensitive marker to podocyte adaption and injury, which was down 
regulated in all animal models tested except functional injury model. In the opposite, CYTC 
was upregulated only in the drug-induced toxicity model. 
By combining the in situ localization of these newly characterized markers with the well 
validated kidney injury molecule -1 (KIM-1), it was possible to follow the sequence of 
events from early podocyte injury to entire proximal tubule damage. Hence, this represents 
a valuable tool for exploring the pathogenesis of glomerulopathy.  
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2. Introduction 
 
1.1 Functional anatomy of the nephron and glomerulus 
 
The urinary system is composed of a pair of kidneys and ureters, the bladder, and the 
urethra. This system accomplishes a variety of functions contributing to maintain body 
homeostasis. 
The role of the kidneys is to excrete water-soluble metabolites (e.g. urea) and regulate the 
fluid and electrolyte balance of the body. They are the site of production of renin, a 
hormone and enzyme that participates to the regulation of the blood pressure by cleaving 
the circulating angiotensinogen into angiotensin I. The kidneys also produce 
erythropoietin, a cytokine that stimulates the production of erythrocytes. 
 
Anatomically, the kidney is composed of a cortex and a medulla that are further divided 
into sub parts. The functional unit of the kidney is the nephron and is composed of the 
following elements: 
• renal corpuscle 
• proximal convoluted tubule 
• thin and thick limbs of the nephron loop (loop of Henle) 
• distal convoluted tubule 
• collecting tubule 
 
An illustration is shown in Figure 1. 
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Figure 1: The structure of kidney nephron. Source: “Blood Flow in the Nephron” by Phil Schatz. 
License: CC BY 4.0  or Wikipedia, the free encyclopedia. 
 
 
The nephron is starting with a structure called the renal corpuscle which is the initial 
blood-filtering unit and is composed of two parts: the glomerulus and the Bowman’s 
capsule. The glomerulus is a tuft of small blood vessels (capillaries) and is inserted into the 
Bowman’s capsule. The inner layer (visceral layer) of the capsule closely envelops the 
glomerular capillaries and is composed of highly specialized epithelial cells called 
podocytes (Figure 2), whereas the outer layer (parietal layer) consists of a simple 
squamous epithelium supported externally by a basal lamina and a thin layer of reticular 
fibers. Between the two capsular layers is the urinary space (also called the capsular space) 
which receives the fluid filtered through the capillary wall and the visceral layer. 
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Figure 2: The renal glomerulus. Source: Wikipedia, the free encyclopedia. 
 
 
The main function of the glomerulus is to constitute an efficient filtration barrier. This 
barrier is composed of the glomerular endothelial cells, the glomerular basement 
membrane and the podocytes. 
The capillary loops of the glomerulus are covered by these specialized endothelial cells 
with large fenestrae. In between the capillaries, modified smooth muscle cells called 
mesangial cells, regulate blood flow by their contractile activity and secrete extracellular 
matrix, prostaglandins and cytokines.  
Between the highly fenestrated endothelial cells of the capillaries and the podocyte there is 
a thick glomerular basement membrane (GBM). This membrane is the most significant part 
of the filtration barrier separating the blood in the capillaries from the urinary space. This 
GBM is formed by the apposition of basal laminae produced by the capillaries and the 
 Page 11 
podocytes and composed of three layers: lamina rara externa, lamina densa, and lamina 
rara interna. The lamina rara externa is adjacent to the podocyte processes. The lamina 
densa is the central layer composed mainly of type IV collagen and the lamina interna is 
adjacent to the endothelial cells. 
The podocytes have a large cell body from which arise several primary processes that give 
raised to secondary cytoplasmic processes. These are three morphologically and 
physiologically different segments: the cell body, the major process and the foot processes. 
The cell body of the podocyte is not in direct contact with the basement membrane of the 
capillaries whereas each foot process is. The foot processes arise from the split of the major 
processes and contain an actin-based cytoskeleton that is linked to the GBM. The podocytes 
form a highly branched interdigitating network: the foot processes of one podocyte are 
connected 2 by 2 with the foot processes of an adjacent podocyte and this arrangement 
forms a filtration slit called the slit diaphragm.  The slit diaphragm is a highly specialized 
type of intercellular junction made of modified adherent junctions and constitutes the final 
barrier avoiding protein loss during the filtration process. (Junqueira’s Basic Histology 
book. 12th edition. 2009). One of the most important components of the slit diaphragm is a 
large transmembrane protein called nephrin. 
This glomerular barrier is permeable to water, ions and small molecules. It filters 
molecules circulating in the bloodstream into the Bowman's space and allows 
discrimination among various protein molecules based on their size (e.g. albumin or 
protein with molecular weight higher than 70 kilodaltons) and their charge (e.g. negatively 
charged molecules). The barrier prevents the passage of large molecules into the Bowman’s 
space and keeps them in the blood stream.  The molecules that pass through the filtration 
barrier enter the Bowman’s space and flows into the lumen of the proximal convoluted 
tubule and became the glomerular filtrate. The rate at which the glomerulus filters the 
plasma is called the glomerular filtration rate (GFR). It is important to notice that the 
filtration rate is much higher than the flow in systemic capillaries because the glomerular 
capillaries are connected at both ends to high-resistance arterioles, the afferent arteriole 
and the efferent arteriole. This anatomical feature creates a high hydrostatic pressure in 
the glomerular capillaries, which is one of the forces that favor filtration through the 
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Bowman's capsule. The glomerular filtrate exits the glomerulus through the proximal 
convoluted tubule and is then further processed along the nephron to form the urine 
(Boron WF., Boulapep E:  Medical Physiology (2nd ed.). 2012) 
 
The general anatomy of the kidney varies between the different species, in particular 
between human and rodents. These inter-species differences have to be taken into account 
during the test of new drugs and in particular when trying to interpret the significance for 
humans for drug induced phenomenon observed in kidneys of laboratory rats.  At the 
morphological level, the rat kidney is composed of one single lobe whereas human kidney 
contains a minimum of 8 to 11 cone-shaped renal lobes, each composed of a central conical 
medullary pyramid surrounded by a cap of cortex. In the rat, the glomerular filtration rate 
can be variable when this parameter stays absolutely stable in human.  The rat has also the 
ability to concentrate urine about twice more than in human. This peculiarity of rat renal 
physiology is an evolutionary adaptation to a dry climate. The osmotic ratio (urine/plasma) 
for man is 4.2 whilst is 8.9 for rat. The difference in urine concentration capacity is the 
result of functional anatomical differences between the two species. Compared to the 
cortex, the relative medullary thickness of the human kidney is 3.0 with 14% long-looped 
nephrons, whereas the relative medullary thickness of the rat kidney is 5.8 with 25% long-
looped nephrons (M. Suckow, S. Weisbroth: The Laboratory Rat. 2005).  
In addition to the morphological and anatomical differences, the rat shows some specific 
biochemical characteristics and can for example very easily eliminate cholesterol from the 
plasma using muricholic acids, which are a group of bile acids found mainly in mice and 
rats and at low concentrations in other species. 
The alpha-2 microglobulin induced nephropathy is also a known example of rat specific 
pathology. This protein belongs to the lipocalin family which is characterized by the ability 
to bind a range of small hydrophobic molecules and to form complexes with soluble 
macromolecules. They act in the general clearance of endogenous and exogenous 
compounds (Flower 1996). The alpha 2-microglobulin nephropathy is an important 
toxicological syndrome that occurs in male rats following exposure to a number of 
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important industrial and environmental chemicals. This protein is produced in large 
amounts by the liver of male rat and reversibly binds to chemicals (and/or their 
metabolites). The complex formed is resistant to proteolytic hydrolysis and lead to 
accumulation in renal lysosomes before creating a subsequent cytotoxicity and cell death 
(Swenberg, Short et al. 1989). This is an example of syndrome highly species and sex 
specific that is important to know and to take in consideration when the rat data are 
analyzed to determine the relevance for human risk assessment.  
 
1.2 Podocytes alteration and proteinuria 
 
The glomerular filtration barrier is very sophisticated and an efficient filtration device but 
at the same time, it is also the most vulnerable component of the kidney.  
As any other cell, the podocyte needs to maintain homeostasis that requires permanent 
adjustment based on the variations of neighbors cells, metabolism variations … etc. In case 
of physiologic stress and pathologic stimuli, all the cells need to adapt reaching a new 
steady state that allows their survival and function. This adaption is a reversible functional 
and structural response and may consist of an increase in cell size (hypertrophy) and 
functional activity, an increase in cell number (hyperplasia), a decrease in the size and the 
metabolic activity (atrophy) or a change in the phenotype of the cells (metaplasia). When 
the stress stimulus is eliminated, the cell can return to the original state without having 
suffered any harmful consequences. If the limits of the adaptive response are exceeded or if 
the cells are exposed to injurious agent, there is an injury. The cell injury is reversible up to 
a certain point, but if the stimulus persists or is severe enough, the cell suffers irreversible 
injury and ultimately cells death.  (Robbins & Cotran Pathologic Basis of Disease (8th 
Edition), 2009). 
The podocyte is a terminal differentiated neuron-like epithelial cell which has a very 
limited capacity of division and replacement. The podocyte main function in the kidney is 
to maintain the glomerular basement membrane filtration mechanism and is playing a key 
role to ensure the proper selectivity of the filter. Therefore, it is crucial that the podocyte 
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ensures a continuous performance. However, if the stress persists or is intense enough, the 
podocyte can irreversibly suffer and shed into the urine or show signs of chronic 
degeneration.  
The main adaptation mechanism of the podocyte is hypertrophy and was studied by 
Wiggins et al. in 2005 (Wiggins, Goyal et al. 2005) in the aging rat. They showed that the 
podocyte is compensating its low capacity to divide by hypertrophy. They could recognize 
5 stages in the hypertrophy process in the way of glomerulosclerosis. The stage 1 has been 
defined as the normal podocytes, stage 2 a non-stressed podocytes hypertrophy, stage 3 an 
adaptive podocytes hypertrophy, stage 4 decompensated podocytes hypertrophy and stage 
5 podocytes depletion. Only stage 4 and 5 are associated with proteinuria (functional 
changes) but changes in the podocytes biology start earlier at stage 3 (e.g. increase 
desmin). 
Aside from aging and in a more general situation, the glomerular response to podocyte 
injury has recently to reviewed by Nagata M. (Nagata 2016). The podocytes can be exposed 
to several type of stress such as mechanical, oxidative or immunological.  The protective 
response of the podocyte to injury such as ischemia, chemical substances and inflammatory 
cells can be the production of reactive oxygen species (ROS) (Diamond, Bonventre et al. 
1986, Chen, Meng et al. 2013).  Another adaptive response of the podocyte against stress is 
upregulation of several  proteins including for instance vimentin and desmin (Shimojo 
1998).  Occasionally other molecule can be transiently expressed e.g. Notch (Niranjan, 
Bielesz et al. 2008). 
In an injured podocyte, cell death mechanisms are possible and the autophagy process is 
particularly important for post mitotic cells with highly branched cellular processes like 
podocytes or neuronal cells. Autophagosomes have been found in normal (resting) 
podocytes of mouse (Mizushima, Yamamoto et al. 2004) and human (Sato, Adachi et al. 
2006) which implies a high level of basal autophagy activity in the podocytes. 
In their mini-review, T. Weide and T. Huber (Weide and Huber 2011) focused on autophagy 
as a critical mechanism to maintain glomerular homeostasis. The efficiency of autophagy 
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seems to counterbalance intracellular oxidative stress. Under pathological conditions, the 
loss of autophagy appears to increase dramatically the susceptibility to glomerular disease: 
reduction of the basal level of autophagy flux promotes cytoplasmic accumulation damaged 
organelles and protein aggregates, leading of oxidative stress, ER stress, inflammation and 
apoptosis. Therefore, defective autophagy in podocytes accelerates glomerular damage 
after the induction of glomerular injuries by PAN (Fougeray and Pallet 2015).  
When the podocyte injury reaches a certain level of severity, it has some clinical 
consequences including proteinuria and decreased renal function which account for the 
vast majority of end-stage kidney diseases. The glomerular proteinuria is associated with 
loss of albumin and high molecular weight proteins. When the podocytes are injured, the 
foot processes simplify or lose their normal interdigitating pattern (referred to as 
effacement of the foot processes) and the slit diaphragm is disrupted. These changes are 
associated with a reorganization of the actin cytoskeleton (Mundel and Reiser 2010) (see 
Figure 3). 
   
Figure 3: Foot effacement process following podocyte injury. Source: Mundel and Reiser, 2010.  
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When the proteinuria persists, proteins leaking through the filter are damaging the tubules, 
impairing their function. As the function of the tubules worsens, the blood flow to the 
affected nephrons is reduced. Simultaneously, damaged podocytes are producing cytokines 
that modulate the activity and the phenotype of endothelial and mesangial cells in the 
glomerulus. The combination of these two phenomena leads to glomerulosclerosis and to 
further reduction of the renal function (Shankland 2006). The foot process effacement is 
usually considered irreversible at this stage. 
Several diseases are associated with alteration of the glomerular barrier (and/or podocytes 
alteration). Their etiology is variable: 
- Immunological mechanisms underlie most forms of glomerulonephritis and/or 
glomerular disorders: either antibodies react with antigens in the glomerular basement 
membrane (e.g. anti-GBM; Heymann nephritis) or the antibodies react with non-glomerular 
antigen in the circulation to form an immune complex that are deposited in the glomerulus. 
- Epithelial cells injury induced by certain mediators:  cells and molecules related to acute 
and chronic inflammation are involved and an inflammation reaction occurs in the 
glomeruli. 
- Abnormality of the structure of the GBM: Genetic predisposition: e.g. hereditary nephritis 
including X-linked nephritis; or non-enzymatic glycosylation of GBM proteins in diabetes. 
- Drug induced glomerulopathies are rare, in comparison to other causes of drug induced 
kidney injury (Izzedine, Launay-Vacher et al. 2006).  The most common underlying 
mechanism is immune activation as seen in drug-induced, ANCA-associated vasculitis 
(AAV), drug-induced lupus (DIL), and drug-associated membranous nephropathy (MN) 
(Hogan, Markowitz et al. 2015). However, there is an increasing number of reports of direct 
drug-induced podocytopathy such as minimal-change disease (MCD) and focal and 
segmental glomerulosclerosis (FSGS) (Markowitz, Bomback et al. 2015).  
Although severe glomerular lesions result in proteinuria, they are not the only cause that 
can induce this phenomenon. There is a tubular proteinuria, overflow proteinuria or 
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exercise-induced proteinuria. The classification is based on the amount of protein, the type 
of protein (albumin or low molecular weight proteins) or the underlying pathological 
damage. As example, the tubular proteinuria occurs most commonly in disease processes 
affecting the tubulo-interstitial component of the kidney and low molecular proteins such 
as beta-2 microglobulin, which are normally completely reabsorbed by proximal tubules 
will be present in the urine. The overflow proteinuria results from an increased excretion 
of low molecular weight proteins in the urine (e.g. production of paraprotein in case of 
multiple myeloma). In this case, the proteinuria results from the amount of filtered protein 
exceeding the reabsorption capacity of the proximal tubule. Similarly the exercise-induced 
proteinuria results from an increased urinary excretion of proteins from plasma origin 
during the physical exercise. This proteinuria is transient and is not associated with any 
particular renal disease.  In spite of the different type of proteinuria, the proteinuria 
associated to glomerular barrier remains of particularly importance regarding the kidney 
function and kidney diseases.  
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2.3 An approach to better characterize podocytes lesions 
 
A Predictive Safety Testing Consortium composed of pharmaceutical industry, academic 
partners and health authorities was built some years ago, with the aim to evaluate 
biomarkers of kidney injury for potential regulatory use in drug safety assessment 
(Dieterle, Sistare et al. 2010). Although seven markers were identified and accepted by 
health authorities as renal biomarkers for detection of acute drug-induced renal toxicity 
(Dieterle, Perentes et al. 2010), glomerular diseases and podocyte injury which is playing 
an important role in progressive renal dysfunction were not explored. 
Currently, the gold standard method to detect podocyte abnormalities requires electron 
microscopy. Immunohistochemistry, for specific markers has been considered as a 
complementary method (e.g. desmin or Angiopoietin-Like-4), but so far, only advanced 
stages of podocyte damage were detectable (Herrmann, Tozzo et al. 2012, Li, Chen et al. 
2015). 
The focus of the present work was to detect the podocyte injury and the integrity of 
filtration barrier function in the context of renal toxicity. To better understand alteration of 
podocyte in glomerular disease, it would require improved in situ tools, which detect and 
differentiate podocyte adaption (stage of reversible injury) from non-reversible injury and 
monitor the onset and progression of damage in the entire nephron. 
The present study aimed at identifying podocyte markers that can be used for studying the 
podocyte in-situ. A stepwise molecular approach was carried out, which lead to the 
identification of new podocyte injury markers.  
• At first, gene expression profiling was conducted from laser captured 
microdissected glomeruli from healthy rat kidney sections and novel markers were 
identified 
• Then, the presence of newly identify markers (Sema3G and CYTC) was further 
explored by immunohistochemistry and in-situ hybridization of rat kidney sections.  
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• Next, the in situ modulation of the Sema3G and CYTC were further studied in several 
podocyte injury animals model  
• Finally, the interplay of Sema3G and CYTC and potential tubular injury related to the 
barrier dysfunction was explored by assessing KIM-1 expression and modulation. 
This approach is suitable for early detection of podocyte dysfunction and for evaluating the 
impact of injury on the entire nephron. Such a tool is applicable in the context of 
investigative toxicological studies, animal models or human clinical case studies. In 
preclinical toxicology studies, detection of early alterations and understanding of lesion 
progression, are a prerequisite and indispensable for renal safety assessment in support of 
the development of new drugs.  
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3. Animal models with proteinuria 
 
A very comprehensive review of the different rodent models to study podocytes diseases 
have been published by Pippin J.W in 2009 (Pippin, Brinkkoetter et al. 2009). This review 
was very useful to select the models that would support the best our goal to study the 
different case of podocyte injury and proteinuria. 
The choice of the rodent models is recommended by the author because of their low cost 
and maintenance. The choice of the rat is related to the fact that the models are well-
defined in this species and that the rat is the species used for toxicological study. However, 
a word of caution would be that the reactivity and sensitivity of this species has the 
disadvantage to be strain dependent. 
The animal model needs to have the podocytes as the primary cells undergoing acquired 
forms of injury and respond to changes. Care should be taken to avoid models where 
endothelial cells, parietal epithelial cells, GBM or mesangial cells are targeted and 
podocytes then respond to that injury in a second step. 
All the models chosen summarize different cases of podocyte injury and may be 
representative of the human pathology but not always and in this case would exhibit a 
specific response of the podocytes to injury. 
 
The selected models are: 
- a model of albumin overload that don’t reproduce an precise human pathology but 
allows to study the slit diaphragm abnormality. This is a functional impairment 
model where the damage on podocyte depends from the dose and duration of 
albumin injection. With short treatment, the podocyte remains intact and there is no 
cellular stress visible. The foot process effacement is reversible. 
- a model of immune deposition that reproduce the human membranous 
nephropathy. This model will represent a model of structural impairment. The 
podocyte is lying on an irregular glomerular basement membrane, affecting its 
stability. In this situation of stress, the podocyte is in adaptive stage (reversible 
injury) 
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- a model of drug-induced toxicity using a glomerular toxicant (e.g. puromycin 
aminonucleoside) that will be compare to a tubular toxicant (e.g. cisplatin). With 
puromycin aminonucleoside (PAN), the podocyte is affected by a direct drug-
induced toxicity and the foot process effacement is associated with cytoskeletal 
changes and apoptosis. The injury is irreversible, 
 
3.1 Model of albumin overload 
 
The glomerulus is restricting the passage of albumin and many other plasma proteins by 
forming a selective barrier based on the size and the charge of the molecules. This barrier is 
composed by the fenestrated glomerular endothelium, the glomerular basement 
membrane, but the slit diaphragm between podocytes foot processes is the major 
component of the size-selective filtration barrier. The podocytes are located on the extra-
capillary side of the glomerular basement membrane and are normally protected from high 
concentration of plasma proteins. In case of filtration machinery damage, albumin and 
other protein will permeate the impaired slit diaphragm or effaced foot process and 
podocytes will be exposed to elevated concentrations. The model of albumin overload is a 
useful model to study the response of a podocytes submitted to a temporary functional 
impairment situation and to study the related molecular/cellular events.  This model is not 
really representing a specific human disease entity.  
 
An in vivo model of albumin overload was first described by Davies and Brewer in 1977 
(Davies and Brewer 1977). They could observe that rats injected intraperitoneally with 1 g 
of bovine serum albumin (BSA) daily for 5 days develop heavy proteinuria and there is 
swelling and loss of the foot processes of the glomerular epithelial cells. Proteinuria 
persists when the injections of BSA are stopped. The persisting proteinuria is caused by 
glomerular damage resulting from disruption and necrosis of the glomerular epithelial cells 
leading to complete sclerosis of glomeruli. The presence of macromolecules abnormally 
filtered into the proteinuric proximal tubule is also causing a dysregulation of the signaling 
and the phenotype of the proximal tubule epithelial cells (Baines and Brunskill 2008). The 
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albumin is endocytosed by the cells of this segment and will increase the production of 
proinflammatory cytokines and profibrogenic cytokines (Eddy and Giachelli 1995). 
Such a model can also be used to verify the accuracy of urinary biomarkers in case of 
proteinuria, in particular low molecular weight markers normally reabsorbed by the 
proximal epithelial cells in a receptor mediated transport (e.g. case of the cystatin C in 
competition with albumin on the same megalin receptor) (Nejat, Hill et al. 2012). 
Several version of the albumin overload protocol exist, starting with the type and the 
species of the protein injected (serum albumin versus globulin), the dosage administrated 
(from 1 to 15 mg/day/g), the route of administration (intra-peritoneal versus intravenous), 
the duration (3-5 days until several weeks) and the rat strain. The different rat strains were 
tested by Lawrence et al (Lawrence and Brewer 1981) and according to their results, the 
injury seems the most severe in male Wistar rats and mildest in male Sprague-Dawley rats. 
The amount of BSA administered correlates with the severity of the glomerular injury and 
the magnitude of proteinuria. By reducing the albumin injection to 2-days only, Yoshida et 
al (Yoshida, Nagase et al. 2008) showed that it is possible to induce podocyte injury and 
apoptosis with a massive urinary proteinuria but without cytotoxic effect of the albumin. 
It has been demonstrated that the podocyte injury was then induced via TGF-B1/p38 
MAPK pathway and was accompanied by albumin deposition and an increase of apoptosis 
(Yoshida, Nagase et al. 2008). 
 
3.2 Model of immune deposition nephrotoxicity 
 
The rat model of passive Heymann nephritis is the most widely studied model of podocyte 
injury. 
This model is a passive model of immunization, that utilizes antiserum against a podocyte 
antigen generated in another animal (often rabbits, goats or sheep), which is injected into a 
rat or mouse to elicit immune complex formation. The initial period of a passive model (5 
to 7 days) is referred as the heterologous phase because it relies on the binding of the 
antibody injected from a foreign source to its target in the host (rat or mouse). 
Subsequently the host develops its own immune response to the deposited heterologous 
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antibody and starts the autologous phase of disease. 
The first model was described by Heymann et al in 1959 (Heymann, Hackel et al. 1959), 
using kidney extracts with Freund’s adjuvant which correspond to an active immune 
model. Later, an insoluble subfraction from rat proximal tubule brush borders termed 
fraction 1A (FxA1) was isolated and used to produce antibodies (Edgington, Glassock et al. 
1967, Edgington, Glassock et al. 1968). The targets of the FxA1 antibody is a 600-kDa 
membrane bound glycoprotein called megalin and a 45-kda protein called receptor 
associated protein (RAP). 
Generally male rats are used and antibody is administrated intravenously or 
intraperitoneally. Controls are done using pre-immune IgG from sheep or saline. 
After injection, the anti-FxA1 antibodies bind to megalin which is expressed on podocytes’ 
foot processes. The antibody is capped and shed into the sub-epithelial space where it 
deposits. It accumulates until obliteration of the slit diaphragm. Sublethal complement 
activation occurs on affected podocytes, causing damage and intracellular signaling 
activation. Four to seven days after injection proteinuria occurs and persists throughout 
the autologous phase of the model. The only histological changes are GBM thickening and 
foot effacement process that can be observed by electron microscopy. 
The PHN model has been proved to be very relevant to human disease and closely follows 
the pathogenesis of human membranous nephropathy. 
 
3.3 Model of drug-induced nephrotoxicity 
 
3.3.1 Glomerular toxicant 
 
The puromycin aminonucleoside (PAN) nephrosis is the experimental prototype for the 
human minimal change disease (MCD) or the focal segmental glomerulosclerosis (FSGS). 
The podocyte is the primary target of the puromycin aminonucleoside (PAN), therefore the 
rat PAN model became a powerful tool for investigating podocytes pathophysiology. 
Puromycin is an aminonucleoside antibiotic produced by the bacterium Streptomyces 
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alboniger that causes premature chain termination during translation taking place in the 
ribosome. PAN causes direct DNA damage via the production of reactive oxygen species. 
Many administration routes can be used (subcutaneous, intraperitoneal or intravenous) 
but this is the cumulative PAN exposure which is critical and determine whether rats 
develop histological features of MCD or FSGS and the progression of the glomerular lesions 
from podocytes effacement to glomerular scarring. Between 2 and 4 days following PAN 
administration, podocytes’ foot processes disorganize into broad expanses of epithelial 
cytoplasm. Podocytes show typical flattening and loss of foot process. After this pre-
proteinuric phase, podocyte detachment and proteinuria occur simultaneously. Proteinuria 
develops between day 4 and 6, peak around day 8 and normalized at 4 weeks. This PAN rat 
model affords the opportunity to evaluate serial changes in the podocytes 
 
3.3.1 Tubular toxicant 
 
Cisplatin (cis-diamminedichloroplatinum[II]) is widely used for chemotherapy to 
efficaciously treat various cancers. But the cisplatin therapy is limited by cellular resistance 
and severe side-effects in normal tissues, like nephrotoxicity, ototoxicity… (Pabla and Dong 
2008). Nephrotoxicity primarily occurs in kidney proximal tubule epithelial cells. Cisplatin 
is cleared by the kidney through glomerular filtration but the uptake of cisplatin in renal 
tubular cells is high, leading to cisplatin accumulation and tubular cell injury and death. 
Two different membrane transporters have been identified to be able to transport 
cisplatin, Ctr1 and OCT2. Ctr1 is highly expressed in adult kidney and is localized to the 
basolateral membrane of the proximal tubule (Pabla, Murphy et al. 2009) but OCT2 has 
been identified as the major determinant of the cisplatin-induced tubular toxicity 
(Yonezawa, Masuda et al. 2005). 
One single injection of cisplatin by intraperitoneal injection (3 mg/kg) is enough to induced 
nephrotoxicity in male rats and represent of good model of tubular toxicity for comparison 
to a glomerulus specific toxicant. 
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4. Material and Method 
 
4.1 Method for Laser capture microdissection of glomeruli 
 
All chemicals and material for Laser capture microdissection (LCM) were provided by 
Applied Biosystems, Rotkreuz, Switzerland. 
LCM was performed on 10 µm thickness frozen section of OCT embedded normal rat 
kidney. The tissue samples were thawed in the cryostat chamber for 30 min before the cut 
and the optimal temperature for sectioning was obtained at -16°C. The sections were 
collected on PEN membrane glass slides, fixed with ethanol 75% for 30 sec, hydrated in 
water for 15 sec, then stained with cresyl violet containing 10U/ml of protector RNAse 
inhibitor, washed in water before deshydratation in increasing concentration of ethanol 
until xylene and air dried. All these steps were performed under RNAse-free conditions and 
using the Histogene® LCM frozen kit according to the manufacturer’s instructions.  
LCM was performed using the Veritas™ system with CapSure® Macro LCM Caps using a 
pulse power of 70mW, 2500 μsec pulse duration.  
A minimum area of 250 000 µm2 area was captured for glomerulus and cortex region 
without glomerulus. RNA was isolated using the Picopure® RNA Isolation kit following 
manufacturer instructions, concentrated in a volume of 11μL and checked with Agilent 
2100 BioAnalyser with RNA 6000 Picochip. (Agilent Technologies AG, Switzerland) for 
quantification and integrity check. 
 
4.2 GeneChip® arrays process 
 
Total RNA extracted from the LCM glomeruli and from the primary culture of rat podocytes 
was further processed for GeneChip® experiments which were conducted at CIToxLAB 
(Evreux, France) using the Rat Genome Rat230 2.0 Arrays (Affymetrix,  Inc.,  Santa  Clara,  
CA,  USA).   
Target preparation was performed with a starting amount of approximately 2 ng of total 
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RNA for the laser captured glomeruli and with a starting amount between 6 and 90 ng for 
the cultured podocytes, unless otherwise specified using the NuGEN OvationPico WTA 
system according to manufacturer’s instruction (NuGEN Technologies Inc.). Briefly, cDNA 
generated by single primer isothermal amplification (SPIA) was fragmented and labeled 
using the Encore Biotin module (NuGEN Technologies Inc.). SPIA cDNA size distribution 
(before and after fragmentation) was confirmed by agarose-gel electrophoresis. 
Approximately 4.55 μg of biotinylated cDNA was hybridized for 18 hours at 45°C on an 
array. The array was washed and stained on Affymetrix Fluidics Workstation 450 and 
scanned on Affymetrix Scanner 3000 according to the manufacturer’s technical manual. 
The scanned image was converted into numerical values of the signal intensity (Signal) and 
into categorical expression level measurement (Absolute Call) using the Affymetrix’s MAS 
5.0 algorithm. The software scaled the average intensity of each chip to a target intensity of 
150.  
4.3 Method for GeneChip® arrays analysis 
 
Microarray expression data were analyzed using a Novartis internal analytical software 
tool (COMPARE 4.7.4. software). An initial filtering of data for each of the experiments was 
done to remove any probe sets that had a mean raw expression value below the fixed 
threshold according to the goal of the experiment (e.g. probe sets with a raw expression 
value (MAS 5.0) <1’000 were filtered out for the laser captured glomeruli analysis in order 
to restrict the analysis to very highly expressed transcripts). The probe sets were also 
selected to have at least 50% of present call in any given group, and probe sets without 
annotation were eliminated. 
Gene signatures relating to relevant biological processes were established using COMPARE 
based on similarity measures across genes and knowledge of the biological function of the 
gene product. For finding transcripts with similar pattern of expression across groups of an 
experimental setup, a transcript of interest was defined and Pearson correlation coefficient 
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was used against the entire data set. For clustering analysis, Pearson coefficient for the 
similarity measure and a complete linkage algorithm were used. 
Signatures were scored as the geometric mean of the fold changes of each transcript 
present in the signature.  
 
4.4 Animal study design for Rat albumin overload model 
 
Podocyte injury induced by albumin overload was performed in male Harlan Sprague-
Dawley rat following a slightly modified experimental method as described by Yoshida et 
al, 2008 (Yoshida, Nagase et al. 2008). 
After seven days of acclimation, rats were placed in metabolic cages for sham urine 
collection then returned in home cages. BSA was dissolved in the morning of the injection 
with the goal to deliver 8.5 mg/g dose without exceeding the NACUC dosing limit. 
Animals were injected intra-peritoneal with BSA (n=5) or with saline solution (n=3) for 4 
consecutive days and placed in metabolic cages after the injection of day 3. Urine was 
collected at day 4. Rats were also sacrificed at day 4 and kidney tissue was collected either 
in 10% neutral buffered formalin solution for further paraffin embedding or frozen in 
isopentane until OCT embedding. 
This study was performed at Novartis Pharma Inc, East Hanover, NJ, USA in compliance 
with the Novartis Animal Care and Use Committee. 
 
4.5 Animal study design for rat Passive Heymann nephritis model 
 
Male Sprague-Dawley rats with a body weight between 176 and 191g were injected 
intravenously either with normal sheep serum (n=6) or with 0.5 ml/100g anti-Fx1A 
antiserum (n=8). Antiserum against Fx1A as well as the sheep serum was purchased from 
Probetex (San Antonio, TX, USA). Rats were euthanized on day 14 and kidney tissue was 
collected and frozen in isopentane until OCT embedding. 
Urine was collected on days 6 and 13 and harvested for determining urinary excretion of 
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albumin. 
This study was performed at Novartis Pharma Inc, East Hanover, NJ, USA in compliance 
with the Novartis Animal Care and Use Committee. 
 
4.6 Animal study design using nephrotoxicants 
 
Two different animal studies were design for testing a known glomerular toxicant 
puromycin aminonucleoside (PAN) and a tubular toxicant Cisplatin. In each study, Wistar 
Han male rats of 11-12 weeks old were used. Rats were randomly assigned to treatment 
(n=6) and control group (n=6). In the PAN study, animals were treated daily by 
intraperitoneal injection at 40mg/kg/day. Control animals were treated with isotonic 
purified solution (0.9% NaCl). Animals were sacrificed after 3, 7 and 14 days. For each time 
point, urine collection was performed and kidney was collected, fixed in 10% buffered 
formalin for 48-72 hours maximum before being processed for paraffin embedding.  
In the Cisplatin study, animals were treated only once by intraperitoneal injection at 3 
mg/kg under a dosage volume of 10 ml/kg. Control animals received isotonic saline 
solution (0.9%NaCl) under the same experimental conditions. On completion of the 
treatment period (days 3, 7, 14), samples collection and tissue processing was collected the 
same way as for the PAN study. 
These two studies were performed at the contract research organization CIToxLab (Evreux, 
France) in compliance with Animal Health regulations, in particular with the Council 
Directive No. 86/609/EEC of 24th November 1986.   
 
4.7 Normal tissue for localization 
 
Rat, mouse, dog and monkey (Cynomolgus monkey) kidney tissues were provided by the 
Molecular localization lab of Novartis Pharma AG, Department of Pre-Clinical safety 
(Discovery and investigative Pathology section) and belong to the lab tissue collection. The 
tissues samples were usually collected from untreated and/or reserve animals of 
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investigative toxicology animal studies performed in conformity with the Swiss Animal 
Welfare Law. 
Human kidney tissue samples were coming from two female healthy donors (Caucasian 
ethnicity) and were purchased from The International Institute for the Advancement of 
Medicine (IIAM, Edison, NJ, USA). The use of these human samples comply with Swiss 
Human Research Act (HRA) as well as any relevant laws, regulations, Novartis policies, 
contents of the informed consent (IC), ethics committee (EC)/ institutional review boards 
(IRB) approval, and/or regulatory authority approval, and with additional requirements 
and standards as described in the NIBR Guidance Document on Human Tissue.  
 
4.8 Immunohistochemistry 
 
Immunohistochemistry (IHC) for CYTC was performed using commercially available 
antibodies from Abcam (Abcam Ltd, Cambridge, UK). The rabbit polyclonal antibody 
ab33487 was used until being discontinued by the provider, and then replaced by the 
rabbit monoclonal antibody ab109508 with similar results. 
For Sema3G, no good and specific antibody working for immunohistochemistry were found 
therefore all the analysis were performed only at mRNA level using in situ hybridization. 
The IHC for neuropilin 2 (NRP2) was done using a rabbit monoclonal antibody from Cell 
Signaling Technology (reference 3366, clone D39A5). 
For all staining, the IHC was performed using the fully automated instrument Ventana 
Discovery® XT (Roche Diagnostics Schweiz AG, Rotkreuz, Switzerland) with Roche 
reagents. Formalin fixed paraffin embedded sections were de-paraffinized and rehydrated 
under solvent-free conditions (EZprep solution) followed by demasking step performed by 
heat retrieval cycles in a citrate or Tris-EDTA based buffer (CC1 solution or RiboCC 
solution, option standard). Subsequently slides were blocked for endogenous avidin/biotin 
activity. The rabbit polyclonal anti-Cystatin C was diluted at 1/50 and incubated for 60min 
at room temperature, whilst the rabbit monoclonal anti-Cystatin C was diluted at 1/10’000 
and incubated for 3 hours. The anti-NRP2 antibody was diluted at 1/50 and incubated for 
1hour. A short post-fixation (glutaraldehyde at 0.05%) was done before applying a biotin 
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conjugated donkey anti-rabbit at 1/500 for 16 min (Jackson Immunoresearch Inc.). 
Detection was performed with a streptavidin-biotin peroxydase detection system 
DABMap® Kit following the manufacturer recommendations. The NRP2 antibody required 
a detection using a ready to use polymer anti-rabbit (UltraMap®-anti-rabbit-HRP 
conjugated) followed by the ChromoMap® detection kit. All slides were counter stained 
with Hematoxylin and bluing reagent, dehydrated and mounted using Pertex™ (Biosystems 
Switzerland AG, Nunningen, Switzerland). 
 
4.9 In situ hybridization 
 
Template for Sema3G, CYTC and KIM-1 riboprobe synthesis was generated by RT-PCR on 
RNA from kidney tissue using self-priming oligonucleotide primers flanked in 5‘ with SP6- 
and T3-promoter recognition sequences (primer sequences available in Table 1 of the 
supplementary data). The purified PCR product was transcribed using T3-RNA polymerase 
(anti-sense) and SP6-RNA polymerase (sense) at 37°C for 2 hours using dNTP containing 
Digoxigenin-UTP according to the manufacturer recommendations (Roche Diagnostics 
Schweiz AG, Rotkreuz, Schwitzerland). The quality and quantity of the riboprobe was 
evaluated using the 2100 BioAnalyzer (Agilent Technologies, Palo Alto, CA). As control of 
quality and specificity, the purified PCR products were submitted for double strand 
sequencing and Blast to the expected sequence (performed by Solvias AG, Kaiseraugst, 
Switzerland). From the primer design step, all the probes were also carefully verified for 
Blast and alignment homologies and in particular the rat semaphorin 3G probe that was 
tested against semaphoring 3A which is known to be highly expressed in the rat kidney. 
 
ISH was performed using the fully automated instrument Ventana Discovery® XT (Roche 
Diagnostics Schweiz AG, Rotkreuz, Schwitzerland). All chemicals were also provided by 
Roche Diagnostics. Briefly, formalin fixed paraffin embedded sections were de-paraffinized 
and rehydrated under solvent-free conditions (EZprep solution). Pretreatment steps were 
done with the RiboMap™ kit following the manufacturer’s instructions.  Cell conditioning 
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(demasking) was performed by heat retrieval cycles in RiboCC solution using option mild 
followed by a complementary enzymatic digestion (Protease 3 for 16 minutes at 37°C). 
Hybridization was performed adding to each slide 200 µl of RiboHybe solution containing a 
DIG-riboprobe and was incubated for 6 hrs. After hybridization sections were washed 3 
times with saline-sodium citrate buffer. The details for probes concentrations and 
hybridization temperatures are summarized in Table 2 of the supplementary data.  
DIG-label probe detection was performed using an Alkaline Phosphatase-conjugated sheep 
anti-digoxigenin antibody (Roche Diagnostics) diluted 1/500 in antibody diluent. Antibody 
incubation was carried out for 32 min at 37°C followed by chromogenic detection using 
BlueMap™ Kit with a substrate incubation time of 6 hrs. Counterstaining using ISH nuclear 
fast red was performed for 4 min. Sections were mounted in glycerol-gelatin mounting 
medium (Sigma-Aldrich Chemie GmbH, Buchs, Switzerland). 
 
4.10 Immunohistochemistry and in situ hybridization on frozen tissues 
 
For the animal model with PHN, only frozen tissues were available and some slight 
adjustments of the protocols had to be performed. 
In this case, cryosections of 10 µm were performed and collected on superfrost plus slides. 
After 30 min drying, the slides were immersed in Shandon™ Formal-Fixx™ solution 
(reference 9990244, Thermo Scientific, Switzerland) for 3 days before transfer in the 
Ventana autostainer and run with the same protocol as FFPE material. 
Also for the model of PHN, one additional molecular marker was run to verify the 
complement deposition after treatment of the animals with the anti-FxA1 antibody. The 
staining was performed by immunofluorescence (IF) using a rabbit polyclonal antibody 
anti-C3c from Dako (Dako Schweiz AG, Baar, Switzerland, article number F0201) 
The IF was performed manually on frozen sections that were fixed for 10 min in acetone. 
Blocking of non-specific background was performed for 30 min using Image-iT FX blocking 
reagent (Invitrogen; Catalog N°: I36933) then sections were washed in IHC amplification 
buffer (ProHisto; Catalog N°: AA4) three times for 5 min. The rabbit anti-c3 complement 
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FITC-conjugated antibody was diluted at 1/10. After incubation, the slides were washed 
again in IHC amplification buffer before being counterstained with DAPI/NucBlue fixed cell 
stain (Molecular probes; Catalog n°: R37606) for 2 min. Reaction was stopped in distillated 
water and slides were mounted with FluoroMount Prolong gold antifade reagent 
(LifeTechnologies; catalog N°: P36930) before fluorescence microscopic observation. 
 
4.11 Image analysis  
 
4.11.1 Scanning of slides and detection of kidney sections 
 
Slides were scanned using the Aperio scanscope AT Turbo slide scanner (Leica, Muttenz, 
Switzerland) using the 40x magnification. 
4.11.2 The image analysis platform 
 
For the detection of glomeruli and the quantitative RNA ISH evaluation based on image 
analysis of the generated images, we used the proprietary image analysis platform 
ASTORIA (Automated Stored Image Analysis) which had been developed (at Novartis AG 
Basel) using Microsoft Visual Studio 2010, and consists of collections of many algorithms 
and modules based on functions from Matrox MIL V9 libraries (Matrox Inc, Quebec, 
Canada) to support the specific analysis of a variety of applications from histological image 
analysis.  ASTORIA provides a simple user interface that allows the selection of algorithms 
and adjustable parameter sets, together with the specification of folders containing tif 
images to be processed. System requirements are a MIL V9 runtime license from Matrox 
(Matrox Inc, Quebec, Canada). ASTORIA generates ASCII text result files comprising 
measurement data such as median, mean and standard deviation for the objects’ optical 
density, and more metadata, for each sample analyzed, and also tables with individual 
morphometric and densitometric data for each glomerulus. 
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4.11.3 Optical density of ISH signal in glomeruli 
 
Forty glomeruli per slide were manually outlined by a human operator. For each image of 
manually outlined glomerulus, the following sequence of steps was performed: 
1. Specific extraction of blue ISH signal spots to support optimum segmentation of the 
glomeruli: top hat on smoothed Green channel of RNA ISH image (2) and subsequent 
iterated top hat based segmentation loop using the top hat gray image as basis. By 
looping through a range of top hat binarization thresholds leads to a growing collection 
of RNA ISH positive areas, referred internally as to “plaques”. 
2. Morphological processing of “RNA ISH plaque” objects followed by a connector 
transformation, linking objects that are sufficiently close to each other and indicative 
for belonging to the same glomerulus, after elimination of white spaces, to avoid 
linking across the Bowman’s space. 
3. Closing holes of connected objects and creation of convex hull in order to identify 
spatially overlapping objects. 
4. Separation of touching “convex hull” objects and morphometric classification (area, 
roundness, elongation…) 
5. Locally refined removal of “white space” 
6. Final sequence of morphological transformations (closing holes, separation, opening, 
size filter) 
7. Final individual analysis of objects: optical density measurement for valid glomeruli. 
8. “Specific optical density” which has been described to reflect the amount of protein 
(antigen) concentration, based on measuring and using the staining intensity of an 
appropriate antibody in a non-linear way (Rahier, Stevens et al. 1989, Ruifrok and 
Johnston 2001) was measured for each glomerulus, using the Green channel image of 
the RNA ISH image. In our case, the “specific optical density” reflects the amount of 
mRNA concentration. For the specimen background reference necessary for OD 
measurement, a ring around each glomerulus was determined through several 
dilations and subtraction of the glomerulus mask. 
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9. For each sample, a text file containing a table with entries of morphometric and 
densitometric values for each object considered to be a valid glomerulus was 
generated, providing the basis for further statistical analysis. 
 
4.12 Method for culture of primary podocytes 
 
Isolation and primary culture of the rat podocytes was done accordingly to the improved 
method described by Katsuya K et al. in 2006 (Katsuya, Yaoita et al. 2006). 
Male Wistar adult rats of weight between 250 and 400 g were anaesthetized with a 
pentobarbital solution at 75 mg/kg by an intra-peritonal injection of 1.5 ml/kg. 
A perfusion of the kidney was performed by inserting a catheter below the renal arteries 
into the aorta, before cutting the vena cava and perfusing the kidney with Hank's Balanced 
Salt Solution (HBSS)-/- using a peristaltic pump injecting 12 ml of solution in 2 min. The 
HBSS-/- solution was then replaced by a perfusion solution containing 15 ml of HBSS + 0.9 
ml of Dynabeads M-450 tosylactivated deactivated (2.4x10e7 beads) (reference 140-13, 
Life Technologies AG, Switzerland) and 15 mg of iron powder ( reference 44890, Sigma-
Aldrich, Buchs, Switzerland) for additional 2 min. 
The perfused kidneys were then carefully removed from the abdominal cavity and put in a 
petri dish containing HBSS. Only the kidney cortex was kept, cut in small pieces and placed 
in a digestion solution based on collagenase A at 1 mg/ml (reference 11088793001, Roche 
Diagnostics, Rotkreuz, Switerland) and deoxyribonuclease I at 10’000 U (reference 
4536282001, Roche Diagnostics, Rotkreuz, Switzerland) in 25 ml of HBSS. 
The enzymatic digestion will take place under stirrer (helical tool) at 37°C rotation at 4-5 
rpm for 60 minutes. At the end of the digestion, the collagenase-digested tissue will be 
filtered through a 100 µm cell stainer, wash in HBSS -/- and distributed in 15 ml tubes. The 
tubes are then placed in to the Dyna Mag2- magnet in order to recover the glomerulus 
containing the magnetic beads previously perfused and blocked in the glomerular 
capillaries. The liquid is discarded. The magnetic isolated glomeruli were washed 4x times 
with 5 ml of PBS. The suspension was filtered through a 70 µm cell stainer and was 
reversed in a petri dish before being again submitted to the DynaMag2 magnet. The 
 Page 35 
isolated glomeruli were collected and put in DMEM/F12 based culture medium with fetal 
bovine serum and Penicilline-streptavidin. The obtained glomeruli were counted and 
seeded between 7’000 and 10’000 glomeruli per well using 6-well plates coated with 
collagen I (reference 356400, Becton Dickinson, Allschwil, Switzerland). 
The 6-well plates were put in incubator at 37°C and not touched for 4 days in order to 
obtain glomeruli attachment to the plate and favors the cellular outgrowths. 
After 4-days, the cells were rinsed with TrypLE express (trypsin based solution, reference 
12604013, Life Technologies, Switzerland) and incubated with this solution for 2 to 4 
minutes. Cells were scraped and transferred in 15 ml tubes containing 2-3 ml of culture 
medium, centrifuged at 250 rpm for 5 min. Supernatant was discarded and the pellet was 
suspended in fresh medium and submitted to magnetic isolation to remove the remaining 
glomeruli and collect only the isolated cells (podocytes). The cells were counted in 
haemometer counting chamber with trypan blue. Density was adjusted to 30’000 cells/well 
using a 96-wells plate coated with collagen I (reference 336407, Becton Dickinson, 
Allschwil, Switzerland). 
 
 
4.12.1 Drug treatment of the primary culture of rat podocytes 
 
 The drug treatment was performed the day after the seeding. 
A preliminary step of dose range finding was necessary to determine an appropriate 
treatment dose for Puromycin aminonucleoside (PAN) that avoided cell toxicity (reference 
P7130, Sigma-Aldrich, Buchs, Switzerland). The first panel of concentrations tested for PAN 
was between 0, 25, 50, 100 and 150µg/ml (Figure 4) and was then further refined with 
lower concentrations between 0 and 2 µg/ml (Figure 4). For cisplatin (reference 
C2210000, Sigma-Aldrich, Buchs, Switzerland), increasing concentration from 0, 1.5, 3, 6, 
12, 25, 50 and 100 µM were tested without any problems of viability. The dose of 50 µM 
was chosen for cisplatin and two concentrations of PAN were defined as low dose 
(0.1µg/ml) and high dose (1 µg/ml). 
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Figure 4: Viability test results after treatment of the primary podocytes with increasing 
concentrations of PAN and cisplatin. 
 
 
The compounds were diluted in such a way that 50µL of culture medium from each well 
can be exchange with 50µL of diluted compounds. 
Compounds were incubated for different end points: 3h, 6h, 24h and 48h. Then, an aliquot 
of supernatant was collected for the viability test and the cells were washed with PBS 
before being lysed with 30 µl of QIAzol Lysis Reagent (reference 79306, Qiagen, 
Hombrechtikon, Switzerland) stored at -80°C until further processing for RNA extraction 
using the Qiagen RNAeasy mini-kit (reference 74104, Qiagen, Hombrechtikon, Switzerland)  
following the provider instructions. 
The extracted RNAs were processed for GeneChip® experiments as already described 
previously. 
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4.12.2 Characterization of the primary podocytes using immunofluorescence 
 
Aside from the treatments, some of the cells were plated on chamber slides and incubated 
the same way as the treated samples. No drug treatment was applied on it. At the end of the 
experiment, the cells were washed with PBS and fixed in PFA 4% in PBS for 10 minutes at 
room temperature. After the fixation, the cells were washed again in PBS and 
permeabilized with a Triton-X100 solution at 0.25% in PBS at room temperature for 15 
minutes. Before applying the primary antibodies, a blocking step of 30 minutes was 
performed using Image IT fix signal enhancer solution (reference I36933, Invitrogen, 
Switzerland). The primary antibodies rabbit anti-podocin (reference P0372, Sigma) and 
mouse anti-synaptopodin (clone Q1D4, reference 65294, Progen) were diluted at 1/500 
and 1/50 respectively in amplifying antibody dilution buffer (ready to use solution 
reference AA3, ProHisto) and were incubated overnight at 4°C. The next day, a goat anti-
rabbit Alexa-488 conjugated (reference A21206, Invitrogen) diluted at 1/200 was mixed 
with a goat anti-mouse Alexa-546 conjugated (reference A21123, Invitrogen) diluted at 
1/200 and applied for 30 minutes at room temperature. The slides were mounted in 
Prolong gold anti-fade reagent (reference P369303, Invitrogen) after a 2 minutes 
counterstaining using NucBlue fixed cell stain (reference R37606, Invitrogen).      
These two markers podocin and synaptopodin were used as specific markers of podocytes, 
considering that the podocin is a marker of podocytes foot process membrane marker and 
synaptopodin is specific of mature podocytes. 
These two markers in combination with a morphological examination of the cells shape 
should allow a determination if the isolation process and culture generated proper 
podocytes or not. 
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4.13 Dosage of urinary proteinuria or albuminuria 
 
4.13.1 Albumin overload and PHN studies 
 
In these two studies, determination of the presence of albumin in urine samples was 
performed at Novartis Pharma Inc, East Hanover, NJ, USA, at the same place as the animal 
studies occur. 
The animals were individually kept in metabolism cages for urine collection at day 4 
(albumin overload study) and day 7 and 14 (PHN study). Urine samples were harvested 
and analyzed by immunoassay using a coating albumin antibody detected by an HRP-based 
chromogenic detection. The results are expressed in total albumin excretion in 
micrograms. 
 
4.13.2 Puromycin aminonucleoside (PAN) and Cisplatin studies 
 
For these two studies, total protein quantification was done in urine samples. 
The analyses were conducted at the contract research organization CIToxLab (Evreux, 
France) at the same place as the animal studies occur. 
The urine was collected from 2:00 to 8:00 pm and from 8:00 pm to 6:00 am on days 2/3, 
6/7 and 13/14 on fasted animals. For this purpose, the animals were individually placed in 
metabolism cages. During urine collection, the animals had free access to water but not to 
food.  
The urine was collected in tubes without thymol crystals and kept at approximately +4°C 
during the collection period. Urine fractions of 2 ml were centrifuged at +4°C for 30 
minutes at 10,000 g. before to be subjected to urine analysis. 
Total proteins were measured on the automatic analyzer ADVIA 1650 (Bayer HealthCare) 
using the Pyrogallol red method. Results were expressed in g/L. 
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4.14 Method for the fingerprint analysis 
 
Using the Definiens software (Definiens AG, Munich, Germany), the digitally scanned slides 
from the KIM-1 in-situ hybridization staining results were used to process the images in a 
standardized way. Definiens was used to make an evaluation of a phenomenon which is 
segmental and focal. The goal is to look at an entire kidney section and identify where is 
located the primary lesions. The idea is to combine and/or overlap stained area with 
morphological area. Therefore, the following morphological regions have been defined: 
cortex; inner medulla; outer medulla. The limit between outer medulla and cortex was 
defined by the different tissue structure and with help of the interlobular rays. Staining 
results were then measured to provide data on the total amount of stained tissue as well as 
stain relative area versus unstained area.  
These results should illustrate the place where the tubular injury starts and how it 
progress in the different situation of injuries induced in the rat models tested.   
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5. RESULTS 
 
4.15 Identification of glomerular specific markers 
 
The evaluation of new potential podocytes lesion markers starts by identifying a marker 
that would be specific for the glomerulus and may be used as indicator of podocyte 
dysfunction. 
Glomeruli of normal rat kidney tissue sections (average of 50 glomeruli/rat; n=5 rats) were 
isolated by laser capture microdissection and compared to remaining cortical tissue 
devoided of glomeruli. Total RNA was extracted from these samples and a differential 
genomic profile was generated between the two tissue preparations.  
With the data set, the goal was to perform a very stringent analysis that can eliminate all 
transcripts expressed in both tissues (glomerulus and cortex) and to isolate a pure set of 
glomerulus specific genes. The threshold for the average expression level was put high 
(average expression value [MAS 5.0] of >1’000) in order to retain only robustly expressed 
genes and eliminate genes weakly expressed and/or expressed in different cells types 
within the glomerulus. Using this expression level filter, from the 31042 probe sets of the 
chips, 5% of probe sets (1696) were pre-filtered. Probe sets without annotation were also 
removed. The remaining number of probe sets was then 1450. The fold change comparison 
between the two groups considered only probe sets with a minimal up or down-regulation 
of 1.5-fold and differences of group means were further tested by T-Test (alpha 0.05). At 
this point, we find a limited group of 1020 probe set. We still wanted genes strongly 
discriminating glomerulus from cortex, therefore the log2 Fold change value was chosen at 
2.0 (or more) between the two groups. The final list contains 127 probe sets and is 
available in the Supplementary data part (Supplementary Table 3). The transcripts that 
fulfill the selection are visualized by blue circles (upper left corner) in the scatter plot 
correlation picture in Figure 5. 
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Figure 5: Scatter plot correlation between kidney cortex expressed genes versus glomerular 
expressed genes. Data are given as mean expression levels (log2) of individual features gene 
per tissue including all annotated probe sets. The expression threshold for average expression 
>1000 (MAS 5.0) is indicated by a horizontal line.  Dotted lines indicate log2-transformed fold 
changes (FC) thresholds of >│2│. Features gene level with an average expression value >1000 
in glomerulus and at least 4-fold enriched expression over kidney cortex are marked by filled 
blue circles. 
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The heat map visualization confirm the very high specific expression of these genes in 
glomeruli compared to the cortex tissue (Figure 6) 
 
 
Figure 6: Heat map visualization of the glomerulus specific genes. Fold changes (log2) for 
individual samples were calculated as compared to average expression levels for each probe 
set across the 5 cortex samples. Animal numbers indicate samples derived from the same 
individual. 
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The list of 127 glomerulus specific probe sets is expected to contain a mix of genes 
expressed in the different cell types present in the glomerulus, namely podocytes, 
endothelial cells, mesangial cells and eventually some infiltrating cells. The vast majority of 
these 127 transcripts are mainly podocytes-related genes and it was possible to identify 
some well-known molecules already described to be expressed in these cell like 
synaptopodin, nephrin, WT1, some integrins, podocalyxin-like gene, tight junction protein 
1 (ZO1), dendrin (Patrakka and Tryggvason 2010, Greka and Mundel 2012). In the 
opposite, some genes well-known to be expressed in podocytes were missing among these 
podocin (Nphs2) which is unfortunately not covered by the Rat230 2.0 Arrays or TRPC6 
which is detected by the array but that was eliminated from the results because its 
expression was below the expression threshold we applied. 
We found then some genes related to endothelial cells, like Lyve-1 or endothelial PAS 
domain protein 1. Finally, Th1 expression was found, this gene is one well known and used 
marker for mesangial cells (Ricono, Xu et al. 2003). The presence of potential macrophage 
can be expected and in fact some CD68 expression was detected. Renin expression was also 
detected. The fact that this gene is known to be in the juxta-glomerular apparatus (but not 
in the glomerulus per se), confirms that the precision of laser microdissection was sufficient 
to enrich the data set in glomerulus specific genes, but eventually included adjacent tissue 
as e.g. juxta-glomerular apparatus. 
 
In the list of 127 transcripts containing glomerulus specific gene we compiled, there were 
two genes that drawn our attention, Sema3G and Cst3. These two genes ranked 
respectively the second and fourth in terms of highest glomerular mean expression in log2 
scale. When assessing the expression of these 2 genes in the single animals used for this 
analysis, the expression data confirmed that both genes are  expressed at high level in the 
glomerulus of normal kidney (both with average expression [MAS 5.0] around 10’000) with 
strong  reproducibility between the donors (see data details in Figure 7).  
At the time this work was started, an overview of the literature told us that none of them 
were precisely described in the literature for being involved in any podocytes-related 
function. Sema3G seems to be effectively expressed in endothelial cells but is mainly 
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described as guidance molecule (see role and function below) and Cst3 is a well-known 
biomarker of kidney function but is supposed to be only filtered by the glomerulus and not 
synthesize by the cells of the glomerulus.  
This choice was driven by the fact that these two genes were ranked as even more 
glomerular specific genes as synaptopodin or the podocalyxin-like genes and their 
presence among podocyte-specific genes should be in direct relation with this cell and is 
certainly involve in the podocyte function.  
 
 
                   
 
Figure 7: Comparison of Sema3G and CYTC expression levels in the glomerulus versus the cortex 
samples for each single animal  
 
4.15.1 Role and function of Semaphorin 3G 
 
Semaphorin 3G (Sema3G) belongs to the semaphorin family that is a large gene family with 
seven classes. The class 3 semaphorins are composed of semaphorin domain, an 
immunoglobulin domain and a highly basic carboxyl terminus. Class 3 semaphorins are 
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secreted proteins and regulate signaling pathways that control many processes like cell 
adhesion, cytoskeletal dynamics, migration, survival and proliferation of cells. Semaphorin 
3A was the first identified semaphorin in vertebrates on the basis of its ability to induce the 
collapse of axonal growth cones of the dorsal root ganglion (DRG) (Luo, Raible et al. 1993, 
Behar, Mizuno et al. 1999). 
In the opposite, Sema3G is the most recent and unknown semaphoring of the class 3. It was 
identified in 2005 in mouse and was shown by Northern blot to be expressed in adult 
tissue mainly in lung and kidney, moderately in the heart and placenta and slightly in brain. 
Some expression was also detected by in situ hybridization in kidney at E17 (Taniguchi, 
Masuda et al. 2005).  In 2006, Takemoto et al. by screening a large-scale sequenced cDNA 
library from mouse glomeruli at different stages of development, they could find Sema3G 
within the 300 glomerular cell enriched transcripts and within five novel podocytes 
transcript in the E18.5 kidney, without investigating further this marker (Takemoto, He et 
al. 2006). 
Initially, Sema3G has been mainly described for its role as repulsive axon guidance 
signaling molecule (Yu and Moens 2005) but it also has been characterized as attractive 
and repulsive regulators of angiogenesis exerting an autocrine effect of on endothelial cells 
and a paracrine effects on smooth muscle cells (Kutschera, Weber et al. 2011). Sema3G 
specifically was mentioned in the class-3 semaphorins as inhibitors of tumor progression, 
being the only class-3 semaphorin to have a prognostic value in adult gliomas (Karayan-
Tapon, Wager et al. 2008). Recently Sema3G was identified as a PPAR-gamma downstream 
effector which is centrally involved in regulating endothelial cells migration (Liu, Li et al. 
2015). 
The receptor of Sema3G is mainly neuropilin-2 that dimerize with plexin, and it is also 
mainly described for its role in axonal growth and guidance and in physiological and 
pathological angiogenesis.  
Some other class 3 semaphorin family members like Sema3A and 3F have been described 
to be expressed in podocytes, and Sema3A has been shown to regulate the expression and 
interactions of slit-diaphragm proteins and decreases podocyte survival (Guan, Villegas et 
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al. 2006). Now, Sema3G has just been confirmed as novel podocyte gene and that the 
knockout of this gene doesn’t show glomerular defects but aberrant foot process by EM 
(Ishibashi, Takemoto et al. 2016). 
 
4.15.2 Role and function of Cystatin C 
 
Cystatin C (CYTC) is a low molecular weight (13-kD) molecule and consists of 120 amino 
acid residues with two disulfide bridges and belongs to family 2 of the cystatin superfamily. 
CYTC is produced by all nucleated cells (Mussap and Plebani 2004). CYTC is an endogenous 
cysteine proteinase inhibitor and is considered as the physiologically most important 
inhibitor, regulating activities of endogenous cysteine proteinases such as cathepsins B, H, 
L and S in the extracellular environment. Considering that cysteine cathepsins play 
fundamental roles in multiple biological processes such as protein turnover, pro-protein 
processing, antigen presentation and apoptosis, the role of CYTC is related to many 
pathological processes such as cardiovascular disease and apoptosis (Shi, Sukhova et al. 
1999, Turk, Stoka et al. 2012). 
CYTC is mainly used as a biomarker of kidney function. Due to its low molecular weight, 
CYTC is filtered from the blood by the glomerulus then reabsorbed through a megalin-
mediated endocytosis Ca+ dependent manner (Kaseda, Iino et al. 2007) and metabolized by 
proximal tubule cells (PTC). Under normal conditions, the production of CYTC is constant 
and its reabsorption by the PTCs is complete and no CYTC can be found in the urine. 
Because of these properties, CYTC became an interesting marker for clinical use and a 
potential alternative to creatinine measurement. It could replace or supplement serum 
creatinine to estimate the glomerular filtration rate (GFR).  GFR based on serum creatinine 
level are limited by their dependence on muscle mass and CYTC level has the advantage not 
to be influenced by this muscle mass. The performance of cystatin C alone or the 
combination creatinine-cystatin C compared to creatinine-based estimating equations in 
chronic and acute kidney disease has been intensively studied (Inker and Okparavero 
2011). However, it seems that at the end, models based on cystatin C alone are not superior 
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to those based on creatinine, but models based on both markers can improve GFR 
estimation in the reference range (Eriksen, Mathisen et al. 2012). 
In preclinical studies, urinary CYTC has also been proposed for potential detection of both 
glomerular and proximal renal damage and was within the seven biomarkers endorsed by 
the FDA and EMEA for acute kidney injury (Dieterle, Perentes et al. 2010). Recently this 
marker was also tested in rat models of anti-glomerular basement membrane 
glomerulonephritis and Zucker diabetic fatty (ZDF) rats and it was shown that urinary 
CYTC can be a useful marker of renal damage (Togashi, Imura et al. 2013, Togashi and 
Miyamoto 2013). The limitation for the usage of CYTC as a trustful urinary marker has been 
pointed out by Nejat M. in 2012 (Nejat, Hill et al. 2012). CYTC reabsorption is receptor-
mediated using megalin (Kaseda, Iino et al. 2007) but the same receptor is also used by 
albumin.  They could demonstrate that in case of increased albuminuria, the absorption of 
CYTC can be reduced by competitive inhibition. 
Aside from these different roles of CYTC, it was never described and studied in details what 
is the role and regulation of CYTC into the glomerular compartment and how this 
expression is regulated in this part of the kidney under different toxicological and/or 
pathological conditions. 
 
4.15.3 The tubular injury marker KIM-1 
 
In all the coming work, KIM-1 is going to be the tubular injury marker systematically 
associated to the two glomerular markers Sema3G and CYTC in order to have an indicator 
of nephrotoxicity. 
 
KIM-1 has been described for the first time in 1996 by Ichimura et al. (Ichimura, Bonventre 
et al. 1998). KIM-1 is also called Hepatitis A virus cellular receptor 1 (HAVCR1) (Kaplan, 
Totsuka et al. 1996) and T cell Immunoglobulin mucin (TIM-1). KIM-1 is a type I cell 
membrane glycoprotein with a six cysteine immunoglobulin like domain and a mucin 
domain. 
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In the normal kidney KIM-1 is expressed at very low level but as soon as the kidney gets 
injured by toxicants or ischemia, it is immediately upregulated in the cells which are 
dedifferentiated and undergoing replication. KIM-1 has been identified as an important 
player in the restoration of the morphological integrity and function to postischemic 
kidney (Ichimura, Bonventre et al. 1998). Additionally, KIM-1 possesses a single 
transmembrane domain and undergoes membrane-proximal cleavage by 
metalloproteinase, which leads to the release of soluble KIM-1 ectodomain into the urine. 
The constitutive cleavage of KIM-1 is mediated by ERK activation, and is accelerated by p38 
MAP kinase activation (Zhang, Humphreys et al. 2007). This shed ectodomain of KIM-1, 
released in the lumen, is heavily glycosylated and stable and appears in the urine after 
injury. KIM-1 is a phosphatidylserine receptor which recognizes apoptotic cells directing 
them to lysosomes. It also serves as a receptor for oxidized lipoproteins and hence is 
important for uptake of components of the tubular lumen which may be 
immunomodulatory and/or toxic to the cell. Data suggest that KIM-1 expression is 
protective during early injury, whereas in chronic disease states, prolonged KIM-1 
expression may be maladaptive and may represent a target for therapy of chronic kidney 
disease (Bonventre 2014). KIM-1 has been qualified by the United States Food and Drug 
Administration and the European Medicines Agency for preclinical assessment of 
nephrotoxicity. But recent data suggest the importance to monitor KIM-1 for early 
diagnosis and clinical course not only in patients with various forms of AKI and other renal 
diseases but also in patients with cardiorenal syndrome, heart failure, cardiopulmonary 
bypass, cardiothoracic surgical interventions in the pediatric emergency setting, and so 
forth (Medic, Rovcanin et al. 2015). 
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4.16 Expression of Sema3G, CYTC and KIM-1 in normal kidney 
 
In order to confirm the expression of Sema3G and CYTC in podocytes, we proceed with 
their mRNA and protein localization using respectively in-situ hybridization and 
immunohistochemistry on tissue sections of rat kidney. 
 
4.16.1 Embryonic expression of Sema3G and CYTC 
 
The localization of Sema3G and CYTC in the rat embryonic kidney was done by in situ 
hybridization using rat embryos at the stage of E15 days post coitum (dpc), when cortical 
and medullary regions are reasonably well-defined. In the cortical region, substantial 
numbers of primitive glomeruli can be found. More centrally, the medullary region 
principally contains undifferentiated mesenchyme tissue with a few interspersed collecting 
tubules. 
Expression of Sema3G was visible in what was identified as primitive glomeruli, in the cells 
that surround the structure. Some faint signal was sometime visible in the structure close 
to the glomerulus and identified as a primitive tubule but was more likely background.  
No other organ in this section seems to express Sema3G, with the exception of the 
endothelial cells of some blood vessels in the embryonic lung. This result is in agreement 
with the previous observation done by Taniguchi et al. where Sema3G was detected in 
mouse kidney, lung and cerebellum at E17dpc (Taniguchi, Masuda et al. 2005). The 
cerebellum region was not available on the section and therefore the expression in this 
tissue couldn’t be confirmed. 
Similarly, in situ hybridization with the CYTC probe gave some positive signal in the 
primitive glomeruli (at the same location as the Sema3G). Additionally, some signal could 
be find in the brain, potentially in the pons but the precise region was difficult to identify 
on this section. Some isolated circulating cells were also positive. 
The literature review could not find any previously described expression of CYTC in 
embryonic kidney. All published data are describing either the detection of CYTC in serum 
as marker of renal function assessment (Bokenkamp, Dieterich et al. 2001) or the 
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expression of CYTC in blastocysts for supporting the embryonic implementation (Baston-
Buest, Schanz et al. 2010). No description of the tissue distribution of CYTC could be found. 
 
 
 
Figure 8: Expression of Sema3G (A and B) and CYTC (C and D) by ISH in rat embryo at E15dpc 
(Blue: NBT substrate for ISH; Red: counterstaining). (A)(C) are low magnification (x1.25) of 
the entire embryo and (C)(D) are high magnification (x40) of the kidney. Staining for Sema3G 
and CYTC in the primitive glomerulus can be observed. 
 
 
Summary of Sema3G/CYTC embryonic expression 
Expression for Sema3G and CYTC could be detected as early as E15 dpc in the primitive 
glomerulus of rat.  
Additionally some blood vessel seems to express Sema3G. CYTC was also found in 
nervous tissue and isolated circulating cells. 
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4.16.2 Expression of Sema3G in rat adult normal kidney 
 
The expression of Sema3G in rat adult kidney was investigated using in situ hybridization. 
In normal rat kidney, a strong expression of Sema3G was found in the podocytes (Figure 
9A). Podocytes are easily identifiable (also without an H&E staining) based on their size, 
round shape, and location on the internal layer of the Bowman’s space.  
In the rest of the kidney, some expression could be found in the endothelial cells of some 
arteries. The signal intensity was clearly weaker and not all vessels were positive (Figure 
9B). No other region of the kidney showed any signal. 
 
As the neuropilin receptor 2 (NRP2) has been described as the main receptor of Sema3G 
(Taniguchi, Masuda et al. 2005), we localize also NRP2 by immunohistochemistry as 
complementary information. NRP2 has been found not to be expressed in the podocytes of 
the glomerulus but in the parietal epithelial cells of the Bowman’s capsule. We could 
otherwise notice some expression in the endothelial cells in the vessel at proximity of the 
glomerulus, apparently veins or lymphatics but the endothelial cells of the arteries remains 
negative (Figure 10). 
The results on the ligand-receptor localization bring already some information about the 
mode of action of the Sema3G molecule that certainly acts in a paracrine manner in 
glomerulus and autocrine in the vascular bed outside of the glomerulus. 
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Figure 9: Expression of Sema3G by ISH in the podocytes of the glomerulus from rat adult 
kidney (A) and in the endothelial cells of arteries (B) (Magnification x40; Blue: NBT substrate 
for ISH; Red: counterstaining) 
 
 
 
 
Figure 10: Expression of NRP2 by IHC in the parietal epithelial cells of the Bowmann’s capsule 
in the glomerulus of a rat adult kidney (A) and in endothelial cells of the vascular bed (B) 
(Magnification x40; Brown: DAB substrate for IHC; Blue: counterstaining) 
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4.16.3 Expression of CYTC in rat adult normal kidney 
 
Similarly to Sema3G, the staining results at the mRNA level for CYTC showed a strong 
expression in the podocytes (Figure 11). Mesangial cells and endothelial cells of the 
glomerulus remained negative. 
In the cortex region, few isolated cells in the interstitial tissues between the tubules were 
stained positively for CYTC (arrow in Figure 11). Additional positive cells in interstitial 
tissue could be seen in medullary and collecting duct region. These cells seem most likely to 
be circulating cells, located sometimes close to the vessels and distributed in an irregular 
manner. Their frequency was varying from one animal to the other. This seems to correlate 
with previous published data showing that CYTC is produced by macrophages and 
dendritic cells (Xu, Lindemann et al. 2014) . Epithelial cells of the proximal as well as distal 
tubules, loop of Henle and collecting ducts were all negative. 
 
 
 
Figure 11: Expression of CYTC by ISH in the podocytes of the glomerulus from rat adult 
kidney: (A) overview of the cortex region at magnification x1.25 showing the glomerulus 
specific expression; (B) high magnification of one glomerulus (x40) (Blue: NBT substrate for 
ISH; Red: counterstaining)  
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Now, when comparing the protein expression assessed by immunohistochemistry to the 
mRNA results, immunohistochemistry showed a pretty different pattern of CYTC 
localization (Figure 12). The protein detection showed a cytoplasmic signal in podocytes 
(Figure 12) similarly to the in situ hybridization, but signal was mainly found in the 
cytoplasm of the epithelial cells of the proximal convoluted tubules. Previously, no mRNA 
for CYTC was detected by in-situ hybridization in these cells and this means that CYTC is 
exclusively reabsorb from the lumen of the tubules. The IHC results illustrate the fact that 
CYTC is metabolized in the proximal tubular cells after a reabsorption by the endocytic 
receptor megalin (Kaseda, Iino et al. 2007). 
 
 
 
 
Figure 12: Expression of CYTC by IHC in the podocytes of the glomerulus from rat adult 
kidney: (A) overview of the cortex region at magnification x1.25 showing presence of CYTC in 
the proximal convoluted tubule in the cortex region; (B) high magnification of the glomerulus 
(x40)(Brown: DAB substrate for IHC; Blue: counterstaining) 
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Summary of Sema3G/CYTC expression in adult rat kidney 
The podocytes of the glomerulus are able to synthetize both Sema3G and CYTC.  
The two markers co-localize in the glomerulus and are the only cell type of the 
glomerulus producing these molecules.  
At the protein level, CYTC is also produce in the podocytes but the staining results 
reflect also the reabsorption of the CYTC produced by the proximal convoluted tubules. 
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4.16.4 Expression of KIM-1 in rat adult normal kidney 
 
Normal rat kidney do not expressed any KIM-1 molecule as demonstrated by the fact 
generally no signal is observed when conducting in-situ hybridization with a rat specific 
probe for KIM-1 on a normal rat kidney section (Figure 13A).  
It remains possible to detect few isolated positive cells expressing KIM-1 in the epithelial 
cells of the descending portion of the proximal tubule at the cortico-medullary junction in 
the area corresponding to the segment S3 (see Figure 13B). These scattered positive cells 
are located in healthy tubules without any sign of pathology. The location remains 
restricted to this portion of the proximal tubule. Considering that KIM-1 is supposed to 
reflect any cell injury or cellular stress, this specific pattern illustrates the high 
susceptibility of this segment to hypoxia due to the paucity of peritubular capillaries in the 
outer stripe of rodents. 
 
 
 
 
Figure 13: Expression of KIM-1 by ISH in normal rat kidney: (A) KIM-1 is usually not expressed 
in kidney (magnification x5); Few isolated positive cells (B) and rarely tubules (C) may 
sometime express KIM-1 in the descending portion of the proximal tubule (Magnification x20) 
(Blue: NBT substrate for ISH; Red: counterstaining)  
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4.17 Cross-species expression of Sema3G and CYTC 
 
In order to assess the translational relevance of Sema3G and CYTC podocyte expression, we 
extend the localization analysis to kidney of other species, including human. 
 
4.17.1 Localization of Sema3G in kidney of mouse / dog / monkey / human 
 
The localization results were obtained using an ISH probe specific for each species (mouse 
and dog). For monkey and human, the sequence homology is such that the same probe 
could be used.  
The localization data showed that Sema3G is expressed in the podocytes of the glomerulus 
for all the tested species similarly to the observation in rat. The intensity of the signal 
varies between the species, being strong in mouse and dog but low in monkey. The 
difference of expression may not only relate to the quantity of mRNA present but also to 
the quality/specificity of the probe, therefore no real comparison can be made from a 
quantitative point of view. 
In the vascular bed, some expression could be found time to time in the endothelial cells of 
the blood vessels but remains a rare event. A representative picture of each species is 
shown in Figure 14.  
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Figure 14: Expression of Sema3G by ISH in the glomerulus of (A) mouse, (B) dog, (C) monkey 
and (D) human kidney (Magnification at x40 for mouse and dog and at x20 for monkey and 
human) ( Blue: NBT substrate for ISH; Red: counterstaining) 
 
 
4.17.2 Localization of CYTC in kidney of mouse / dog / monkey / human 
 
 
The expression results for CYTC at the mRNA level have been generated using a specific 
probe for each species (except for monkey and human where the same probe was used). No 
expression of CYTC was found in the podocytes from these species and therefore it seems 
that CYTC expression is characteristic of rat podocytes. 
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 Failure during the staining protocol giving raise to false negative results or any other 
technical issue could be excluded as some remaining expression for CYTC could be seen in 
isolated cells intercalated between the tubule. As described in the rat, these cells certainly 
correspond to circulating macrophage cells. The total absence of CYTC in the podocytes of 
the mouse kidney appears is somewhat unexpected as many genes in both species show a 
similar expression. A representative picture of the glomerulus of each species is shown on 
Figure 15. 
 
 
 
Figure 15: Absence of expression of CYTC by ISH in the glomerulus of (A) mouse, (B) dog, (C) 
monkey and (D) human kidney. Magnification x40 (mouse and dog); x20 (monkey and 
human) (Blue: NBT substrate for ISH; Red: counterstaining) 
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The results of the protein detection were consistent with the mRNA. The same cross-
reacting anti-CYTC antibody was used for all species and no staining was found in 
glomeruli with the exception of rat. Instead, the proximal convoluted tubule cells of the 
different species were showing a similar pattern to the rat with the reabsorbed cystatin C 
accumulating in the cytoplasm of the cells at the apical pole (Figure 16). 
These results suggest that CYTC may play a unique role in the rat glomeruli compared to 
other species where the corresponding function could be supported by another molecule 
or mechanism. But we can also not exclude large variation of expression level in the 
podocytes between the species and CYTC may remain express but at some undetectable 
level by immunohistochemistry 
 
 
Figure 16: Expression of CYTC protein by IHC in the kidney: glomerulus of (A) mouse, (B) dog, 
(C) monkey and (D) human kidney are lacking of CYTC expression. Reabsorbed CYTC is visible 
in proximal tubule. Magnification x40 (mouse and dog); x20(monkey and human) Brown: 
DAB substrate for IHC; Blue: counterstaining 
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Summary of Sema3G/CYTC expression cross-species 
 
The expression of Sema3G is similarly located in the podocytes of all the tested species 
and translates to human. 
 
In the opposite, expression of CYTC in the podocytes seems to be a rat specific location 
and can’t be detected in any other species. This observation indicates that the presence 
of CYTC is either species specific or is expressed at a lower level in the other species 
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4.18 Expression of Sema3G and CYTC in rat models of podocytes injuries 
 
Next we investigated the expression of Sema3G and CYTC in different rat models of 
podocyte injury. These experiments were intended to verify how and if Sema3G and CYTC 
expression changed in the different models and assess their potential as marker of 
podocyte injury at a reversible stage versus irreversible stage or if these markers of 
podocyte injury are in relation with a specific type of injury.  
 
4.18.1 Results of the Albumin overload model 
 
The model of albumin overload according to the method of Yoshida et al, (Yoshida, Nagase 
et al. 2008) is intended to create a functional impairment of the podocytes due to the 
excess of albumin injected. The quantity of albumin used is exceeding the filtering capacity 
of the glomerulus and therefore create some proteinuria. With short treatment duration, 
the podocyte is not damaged but the filtration is impaired and the flow of protein reaching 
the proximal tubule is important. 
 
By histopathology, the kidneys of animals receiving albumin showed excessive 
proteinaceous material in the urinary chamber of the glomeruli and in the tubules. A mild 
degree of tubular dilation was seen in the cortex. 
 
As the primary goal of this model is to create proteinuria, the first parameter to measure is 
the quantity of albumin present in the urine samples of the treated animals in order to 
verify that the model worked properly.  
The urines samples of all animals were collected at day 4 and analyzed as described in the 
material and method section. The results are shown in Figure 17. 
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Figure 17: Dosage of albumin in urine samples of PBS or BSA treated animals. The results of 
the control animals were normalized to 100% and the treatment samples expressed in % of 
controls. The median is shown by the black line in the box. 
 
These data confirmed that the administration of high dose of albumin during 4 consecutive 
days resulted into abnormal release of albumin in the urine and showed that the 
glomerulus was not able anymore to play his role of filtration barrier regarding high 
molecular weight molecules. 
 
The next step is to look how the two podocytes markers Sema3G and CYTC reacted to this 
condition of functional impairment and when the filtration barrier capacity is saturated. 
This question was assessed by in situ hybridization using kidney tissue section of PBS and 
BSA treated animals. The anti-sense probe for Sema3G and CYTC were always tested at the 
same time with their corresponding sense probe using similar conditions and the staining 
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results were given after verification of the negativity with the sense probe. The visual 
evaluation is described after observation of all stained slides. 
The expression of Sema3G and CYTC measured by ISH did not showed any visible 
difference in the staining among the PBS and BSA treated animals. An example of the 
results obtained with the CYTC probe is shown Figure 18. 
 
 
 
Figure 18: Expression of CYTC by ISH in the podocytes of PBS treated rats (A) versus BSA 
treated rat (B): no difference of expression is visible. Magnification x40; Blue: NBT substrate 
for ISH; Red: counterstaining 
 
 
To make a precise evaluation of the expression of these markers, a quantification of the 
mRNA signal using image analysis was performed to confirm this result. 
The specific optimal density was measured in the glomeruli of the tissue section using the 
method described previously in the material and method section. The glomeruli were 
randomly selected and manually drawn (n=40 per slide). Considering that the total number 
of glomeruli in a transversal section is between 200-250 pieces, the selected number of 40 
represents approximatively 20% of the total number of elements. The image analysis 
results are shown in Figure 19 for Sema3G and CYTC. 
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Figure 19: Specific optical density measurement in the glomerulus of PBS or BSA treated rats 
expressed in % of the median of the control. 
 
 
The quantitative results of the analysis for both markers confirmed the visual observation 
and showed that no modification of the Sema3G and CYTC expression is occurring after 
treatment with high dose of albumin, indicating that the situation  of functional impairment 
do not affect the expression of these two markers. 
 
In parallel to the in situ hybridization staining, a second tissue section was used to measure 
the CYTC protein pattern. The staining results with the anti-CYTC antibody showed that 
similarly as the mRNA, the protein detected in the podocytes remains unchanged with or 
without BSA.  
Instead, the evaluation of the reabsorbed CYTC by the proximal tubules cells showed a 
signal that was often diminished in term of intensity and more diffused in the epithelial 
cells (annotation with * in the Figure 20B) instead of the crispy signal in the apical pole of 
the cells usually observed. The lumen of many tubule was also found to be filled with 
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accumulated protein (annotation ** in the Figure 20B). Obviously the reabsorption of CYTC 
by the epithelial cells was impaired or saturated considering the unusual quantity of 
albumin present in the portion of the kidney. This impaired CYTC reabsorption in a 
competitive situation with albumin was described by Nejat et al. (Nejat, Hill et al. 2012) and 
was related to a saturation of their commonly used megalin receptor. A large quantity of 
CYTC was probably released in the urine. 
 
 
 
Figure 20: CYTC protein expression by IHC in the kidney of (A) PBS treated animal and (B) 
BSA treatment animal: No changes in the podocytes can be noticed but impaired reabsorption 
in certain proximal tubule cells (* and **) is visible. Magnification x40; Brown: DAB substrate 
for IHC; Blue: counterstaining. 
 
Considering that the presence of high quantity of albumin in the tubule is “unusual” and 
affecting the reabsorption of CYTC, a “secondary” or “indirect” toxicity of the tubular cells 
can be expected. Therefore, investigations using the injury marker KIM-1 were performed 
by in situ hybridization. 
The staining results with the KIM-1 probe in the PBS treated animals group showed that 
the presence of KIM-1 was rare or restricted to few isolated positive cells in the descending 
portion of the proximal tubule at the cortico-medullary junction. It has to be mentioned 
that one outlier animal was found and this animal showed a damaged nephron expressing 
KIM-1. This animal was not considered for the analysis and discussion. 
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In the BSA treated animal group instead, KIM-1 expression became visible in all animals 
and was broadly distributed in the kidney (cortex and outer medulla). A positive staining 
was found as well in the proximal part of the tubule as in the descending part. In some 
cases, signal could be observed along the entire proximal tubule. 
The cells expressing KIM-1 were either strongly positive or remain completely negative 
without gradient of intensity. The distribution of positive cells/tubules in the cortex was 
relatively randomized. At the junction with the medulla, the presence of positive tubules 
was frequent and was often in dilated tubules. The overall staining gave an impression of 
“patchy distribution”. Some pictures of BSA treated animals are shown Figure 21.  
 
 
Figure 21: KIM-1 expression by ISH in rat kidney after PBS treatment (A: cortex)(B: outer 
medulla): No KIM-1 expression could be detected. After BSA treatment (C: cortex)(D: outer 
medulla): KIM-1 is expressed in damaged tubule. Magnification x40. Blue: NBT substrate for 
ISH; Blue: counterstaining. 
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We attempt to define a global pattern of KIM-1 expression in the different part of the 
kidney. Therefore, the fingerprint described in the material-method part was generated for 
KIM-1. The first step consists in a segmentation that identifies the regions of the kidney: 
cortex, outer-medulla, inner-medulla/pelvis. A none-tissue region was created and 
excluded from the analysis. The second step consists of a sensitive detection of the KIM-1 
signal based on the staining intensity. Segmentation and analysis results are shown in 
Figure 22.  
 
 
 
 
Figure 22: Fingerprint results for the KIM-1 expression pattern by ISH using the Definiens 
software: (A) PBS treated animal, (B) BSA treated animal. The cortex is represented in light 
grey; outer medulla in dark grey; inner medulla/pelvis in grey. The KIM-1 expression is 
represented in white color and appears as patchy signal in the cortex only of BSA treated 
animals. 
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From this global pattern visualization and segmentation, it results that the animal treated 
with BSA showed a patchy distribution profile, equally distributed between the different 
segments of the kidney. When specifically assessing the signal intensity data for the KIM-1 
signal in the 3 segments, the intensity of KIM-1 is distributed between the different 
segments but with higher quantity in cortex compare to medulla (Figure 23). 
This demonstrates that after a functional impairment of the podocytes related to an 
overload of albumin, KIM-1 expression is induced in the proximal tubule cells that are 
receiving a flow of large protein. The injury is distributed all along the proximal tubule in 
cortex until the medulla. 
 
 
Figure 23: KIM-1 quantification in the different segments of the kidney in a situation of 
albumin overload. Analysis was performed by Definiens and results are expressed in relative 
area stained. 
 
 Page 70 
 
Summary of the albumin overload model results 
With a functional alteration of the glomerulus, the expression of Sema3G and CYTC 
remains normal in the podocytes although the filtration barrier affected. 
This abnormal presence of albumin is disturbing the reabsorption of CYTC by the 
proximal tubular cells and is inducing some toxicity as indicated by the tubular injury 
marker KIM-1 all over the proximal tubule. 
 
  
 Page 71 
4.18.2 Results of the Passive Heymann nephritis model 
 
The model of Passive Heymann nephritis is used to reproduce the pathogenesis of human 
membranous nephropathy. This model is characterized by proteinuria, a sub-epithelial 
immune deposition that obscures the slit diaphragm. Complement activation and 
deposition occurs in the glomerular basement membrane and affects the podocytes, 
causing damage and intracellular signaling activation. In this situation, there is a structural 
impairment that leads to podocyte stress and adaption reaction. The only histological 
changes are the thickening of glomerular basement membrane and foot effacement process 
that can usually be observed only by electron microscopy. 
 
The histopathological evaluation of the kidney samples taken from rats treated with anti-
FxA1 antibody was difficult because of the freezing technique chosen for this model. The 
nature and intensity of glomerular changes was difficult to appreciate. Some glomerular 
sections clearly showed hypertrophy or desquamation of podocytes. In the majority of 
animals, foci of minimal tubule-interstitial inflammation were noted. 
 
With the help of immunofluorescence, the deposition can be visualized by using an anti-c3 
complement FITC-conjugated antibody on frozen tissue section and can be observed by 
fluorescent microscopy (Figure 24). At this time point of day 14 post anti-FxA1 injection, 
the presence of complement deposition became clearly visible with this method (green 
signal in Figure 24) and the deposit is classically described as a “string of pearls” pattern in 
the glomerular capillary. 
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Figure 24: Rat glomerulus of anti-FxA1 treated animal (A) and sheep IgG treated animal (B) 
stained with an anti-C3 antibody to verify the deposition complement in the GBM:  Presence of 
complement deposition is visible only after anti-FxA1 treatment. (Magnification x40) (Green: 
anti-c3 detection with Alexa488, Blue: DAPI counterstaining). 
 
 
The presence of signal in the glomeruli of anti-FxA1 treated animals confirms the 
complement deposition by this “string of pearls” pattern when compared to animal treated 
with the anti-sheep Ig only.  In the IgG treated group not any signal could be observed. This 
result confirmed the validity of the model.  
 
The analysis of the urine samples also confirms the development of the disease model. 
Urine was collected at day 6 and 13 and the measurement of the excreted albumin at these 
two time points showed a time related increase of the proteinuria (Figure 25). At day 6, the 
increase of albumin released is still moderate (except one animal which is already quite 
high) but a stronger albuminuria is happening after 13 days. The time point of day 5 is 
usually described as the starting point for proteinuria development during the 
heterologous phase of the disease, followed by the autologous phase of the disease with 
establishment of a stronger proteinuria. Looking at the urinary data, the proteinuria may 
not be very strong but remains enough to conclude of a pathological situation. 
 
A B 
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Figure 25: Dosage of albumin in the urine of anti-sheep IG or anti-FxA1 treated animals.  The 
results of the control animals were normalized to 100% and the treatment samples expressed 
in % of controls. The median is shown by the black line in the box. 
 
 
In this context of proteinuria, the expression of the two podocyte markers has been 
assessed on the frozen tissue sections by in situ hybridization using the same probe and a 
slightly modified protocol for frozen tissue. 
The staining results were more difficult to assess due to the histological quality of the 
samples compared to FFPE but was nevertheless possible to perform the analysis. 
Sema3G staining using ISH tends to show a decrease of the intensity in the podocytes of the 
glomeruli but in some others, the differences are not obvious. It indicates that there are 
some variations and potential intensities of reaction within the same animal. A picture 
from an affected glomerulus is shown in Figure 26. 
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Figure 26: Expression of Sema3G by ISH in the podocytes of sheep IgG (A) and anti-FxA1 (B) 
treated rat (frozen sections). The Sema3G signal is downregulated with anti-FxA1 injection. 
Magnification x40; Blue: NBT substrate for ISH, Blue: counterstaining) 
 
 
In the opposite, the staining for cystatin C at the mRNA level didn’t show any difference 
between the anti-FxA1 and the sheep serum injected animals (data not shown). 
Consistently with the mRNA results, the staining at the protein level did not revealed any 
modification of the expression in podocytes (Figure 27). Also the reabsorption of the 
protein by the epithelial cells of the tubules was not affected. No released of protein in the 
lumen could be detected at any place. No further interpretation of the staining results could 
be done with these samples considering the poor quality of the sections.  
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Figure 27: Expression of CYTC by IHC (frozen section) in the glomerulus of sheep IgG treated 
rats (A) versus anti-FxA1 treated rats (B): No change could be observed. (Magnification x40; 
Brown: DAB substrate for IHC, Blue: counterstaining).  
 
 
The quantification of the mRNA results by image analysis was performed for the ISH 
markers Sema3G and CYTC. In term of method, the same rule used in the analysis of the 
protein overload model was used and 40 manually drawn glomeruli per section were 
analyzed.  
The quantitative image analysis results confirmed the slight decrease of Sema3G 
expression in the glomeruli in the anti-FxA1 treated animals and the changes were 
statistically significant with p<0.05. Instead, no statistically significant change could be 
measured for the expression of CYTC as already observed visually (Figure 28). 
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Figure 28: Specific optical density measurement in the glomerulus of sheep serum or anti-
FxA1 treated rats. Results are expressed in % of the median of the control group. 
 
 
KIM-1 staining on the anti-sheep IgG injected animal tissue samples (control group) was 
globally negative for all animals. In the anti-FxA1 group, KIM-1 expression was clearly 
visible but limited to few enlarged tubules located in the area of the descending portion of 
the proximal tubule. Only one animal was found with some tubules stained in the outer 
cortex. A representative picture is shown in Figure 29.  
The availability of frozen materials only made the fingerprint quantification not feasible 
and only the descriptive expression of KIM-1 expression was possible. 
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Figure 29: Expression of KIM-1 by ISH in the kidney of anti-FxA1 treated animal. (A) The 
cortex region was devoiding of signal when some tubules at the junction between cortex and 
medulla (B) appears positive for KIM-1. (Magnification x20; Blue: NBT substrate for ISH, Red: 
counterstaining) 
 
 
 
Summary of the PHN model results 
The structural model of podocyte injury with complement deposition in the slit 
diaphragm and proteinuria showed a difference of behavior between the two markers 
Sema3G and CYTC.   
In the podocytes, Sema3G expression was decreased when CYTC remains unchanged. 
With this result, Sema3G demonstrate an interesting profile and shows that its 
expression can be modulated in a situation of podocytes adaption related to stress. 
 
The tubular injury as measured by KIM-1 showed a limited toxicity. 
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4.18.3 Results of the nephrotoxicity models 
 
4.18.3.1 Podocyte markers in in vivo rat studies 
 
The podocyte is the primary target of the puromycin aminonucleoside (PAN), therefore the 
PAN rat model became a powerful tool for investigating podocytes pathophysiology. There 
is a progression of the glomerular lesions from podocytes effacement to glomerular 
scarring. The podocytes foot processes disorganize into broad expanses of epithelial 
cytoplasm and show typical flattening and loss of foot process, until podocytes detachment. 
In this situation, this model should allow us to study the reaction of the two markers in a 
clear drug-induced toxicological context. As a comparator model, cisplatin-induced 
nephrotoxicity primarily occurs in kidney proximal tubule epithelial cells. Cisplatin is 
cleared by the kidney through glomerular filtration without damaging the podocytes but 
then the uptake of cisplatin in renal tubular cells is high, leading to cisplatin accumulation 
and tubular cell injury and death.  
By histopathological examination of the kidneys of PAN treated animals, the main lesions 
were seen in the glomeruli, and consisted in minimal or moderate vacuolation and 
mesangial proliferation, but also a slight fibrous thickening of the Bowman’s capsule. 
Minimal tubular changes were observed, mostly tubular basophilia. The glomerular 
changes appeared in few animals on day 7 whereas all animals were affected on day 14. 
The histological lesions observed in rats treated with cisplatin were moderate to severe 
tubular basophilia, sloughing or necrosis alternating with cellular hypertrophy and 
regeneration in both the pars convolute and the pars recta of the proximal tubules. 
The analysis of the total protein in the urine samples was measured at day 3, 7 and 14 in 
the vehicle, PAN and cisplatin treated animals. Under PAN treatment, the level of proteins 
released is increasing only after 14 days of treatment and reveal the loss of function of the 
podocytes. This loss of barrier function is often described to occur earlier (e.g. day 8) but 
was not observed in our case.  
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In comparison, the cisplatin treatment does not modify the level of proteins released by the 
kidney at day 7 and day 14 time points. Instead, there is a transient release of protein at 
day 3 that illustrate the single dose treatment effect and its toxicity effect on the tubular 
cells. This proteinuria is a tubular type proteinuria composed of low molecular proteins 
such as beta-2 microglobulin, which in normal conditions are completely reabsorbed by 
proximal tubules (and not high molecular weight protein as in the glomerular proteinuria).  
It means that at day 3, the tubular function is affected but not the glomerulus and at later 
time point the tubular cells are kind of restoring their capacity of reabsorption (Figure 30). 
 
Figure 30: Proteinuria levels in the urine of PAN and Cisplatin treated animals. The results of 
the control animals were normalized to 100% and the treatment samples expressed in % of 
controls. The median is shown by the black line in the box. 
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Assessment of Sema3G and CYTC in these two toxicity models was conducted.  
In the PAN treatment study, Sema3G was tested by in situ hybridization at all time points 
and compared to the vehicle group. Representative pictures from the different time points 
in animal treated with PAN are show in Figure 31. 
 
Figure 31: Time course of Sema3G expression by ISH in glomerulus after treatment with PAN: 
Podocytes are expressing Sema3G in vehicle group (A). After PAN treatment for 3 days (B), 7 
days (C) and 14 days (D), Sema3G expression is decreased. Magnification x40; Blue: NBT 
substrate for ISH, Red: counterstaining. 
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After treatment with PAN, the expression of Sema3G is similar to vehicle group during the 
first three days. From day 7, the number of podocytes expressing Sema3G seems to be 
reduced and the staining intensity in the cytoplasm of the cells becomes lower. After 14 
days of treatment, the signal for Sema3G continues to reduce and became barely detectable 
in some glomeruli. We can clearly see a time related effect of the treatment on this marker. 
Using the same tissues samples, the expression of CYTC by in situ was performed. Similarly 
to Sema3G, no change occurs at day 3 but instead, the signal for CYTC starts to increase in 
intensity from day 7 until day 14 treatment time point. 
Examples of the result for CYTC expression with PAN treatment are shown in Figure 32. 
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Figure 32: Figure 31: Time course of CYTC expression by ISH in glomerulus after treatment 
with PAN: Podocytes are expressing CYTC in vehicle group (A). After PAN treatment for 3 days 
(B), 7 days (C) and 14 days (D), CYTC expression is increased. Magnification x40; Blue: NBT 
substrate for ISH, Red: counterstaining. 
 
CYTC immunohistochemistry in the same samples demonstrates that CYTC protein 
expression followed the same dynamic of the mRNA. CYTC antibody gave an increasing 
staining intensity in podocytes according to the treatment duration (Figure 33). In the 
tubular compartment, the staining is reduced in epithelial cells of the tubules. Sometimes, 
accumulation of protein could be detected in the lumen of some tubules (not shown). This 
shows that the reabsorption of the CYTC is perturbed compared to the normal situation. 
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Figure 33: Figure 31: Time course of CYTC expression by IHC in glomerulus after treatment 
with PAN: Podocytes are expressing CYTC in vehicle group (A). After PAN treatment for 3 days 
(B), 7 days (C) and 14 days (D), CYTC expression is increased. In the proximal tubule, CYTC 
reabsorption is diminished upon treatment. Magnification x40; Brown: DAB substrate for IHC, 
Blue: counterstaining. 
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In the samples treated with Cisplatin for 3, 7, and 14 days, the results for Sema3G and CYTC 
were as follow: 
The treatment of animals with Cisplatin at 3 mg/kg for the same time points as PAN did not 
change Sema3G expression in the podocytes. The staining intensity remains similar to 
controls independently from the treatment time. Also no changes could be noticed in the 
vascular bed. A picture at day 14 is shown Figure 34. 
 
 
 
Figure 34: Sema3G expression by ISH in the glomerulus after 14-days treatment with 
Cisplatin: between (A) vehicle group and (B) Cisplatin (3mg treatment dose), Sema3G 
expression remains unchanged. Magnification x40 (Blue: NBT substrate for ISH, Red: 
counterstaining) 
 
 
For Cystatin C, the level of mRNA in podocytes was also similar to control animals. The only 
difference noticed was an increased number of circulating cells positives for CYTC. These 
cells were located between the tubules, distributed all around the section but mainly in the 
cortex region and certainly correspond to inflammatory infiltrating cells already described. 
Their quantity varied from animals to animals. 
Similarly, the level of the protein CYTC in podocytes was not affected by cisplatin 
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treatment. Instead, the tubular reabsorption was perturbed. The staining in the epithelial 
cells of the tubule was irregular, quite faint and not following the apical border of the cell. 
The Figure 35 is showing a comparison of CYTC expression in the tubule of normal kidney 
and cisplatin treated kidney. 
It is interesting to notice that the treatment effect on CYTC reabsorption seems to be more 
prominent with PAN than with Cisplatin but it has to be taken in consideration that in this 
model, Cisplatin was given only once at the beginning of the study, as multiple doses would 
have been too toxic for the animals. 
 
 
Figure 35: CYTC protein expression by IHC in the tubular epithelial cells 14-days after 
treatment with Cisplatin: Normal CYTC reabsorption in vehicle group (A) and impaired CYTC 
reabsorption (B) after Cisplatin (3mg treatment dose). Magnification x40 (Brown: DAB 
substrate for IHC; Blue: counterstaining) 
 
All the staining intensities of Sema3G and CYTC mRNA in the glomerulus were measured by 
image analysis using 40 glomeruli. Results for Sema3G are shown in Figure 36 and for 
CYTC in Figure 37. In both graphs, the results are expressed in % of the median of the 
control group. 
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Figure 36 and 37: Quantification of Sema3G and CYTC expression in the podocytes of PAN and 
Cisplatin treated animals for different time point (day 3, 7 and 14) 
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The image analysis data confirmed the visual assessment and confirmed that Sema3G is 
down regulated in a time dependent manner after treatment with the glomerulus-specific 
toxicant PAN. At day 3, the decrease is minimal and remains not statically significant. From 
day 7, the decrease of Sema3G mRNA level is statically significant with a value p<0.05. The 
overall level of Sema3G at day 14 is still decreasing but is not more significant (remain at 
p<0.05) for the reason that the variations between the glomerulus and the animals are 
increasing. Upon treatment with cisplatin, Sema3G expression remains more or less similar 
to the control group at all time points.  
In the CYTC image analysis results, we confirmed that the induction of these two markers is 
anti-correlated but with the difference that the upregulation of CYTC is here already visible 
and statistically significant at day 3 (p<0.01) and became strongly significant (p<0.001) at 
day 7 and day 14. CYTC expression after Cisplatin treatment remains unchanged at any 
time point. 
 
For both markers, it is important to notice that their modulation induced by the treatment 
is anterior at the proteinuria in urine which was present only at the day 14. 
 
 
Summary of the nephrotoxicant model results: in vivo data 
In two models of drug-induced toxicity, 
The podocyte expression of Sema3G and CYTC is affected only with the  
glomerular specific toxicant PAN. 
Both markers are differentially regulated in a time dependent manner and their 
induction is anticipating the proteinuria in the urine. 
 
With the tubular toxicant Cisplatin, both markers remained unchanged in the 
podocytes. The reabsorption of CYTC protein by the proximal convoluted tubules is 
instead affected. 
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4.1.1.1 Tubular injury marker in in vivo rat studies 
 
The last assessment performed on the kidney samples in situation of drug-induced toxicity 
was an evaluation of the tubular damages using KIM-1.  
In the PAN treated animals at day 3, no noticeable changes could be observed compared to 
control in the KIM-1 expression. Except few isolated positive cells at the cortico-medullary 
junction, no expression was detected in the cortex. Only one single animal had some 
positivity in a small part of the cortex region. 
At day 7, some positive cells were sometime detectable in the cortex, in the convoluted 
proximal tubule attached to the glomerulus. The expression of KIM-1 in the descending 
portion of the proximal tubule at the cortico-medullary junction remains rare. The 
observation of positivity in convoluted proximal tubule became quite frequent by looking 
at day 14 treated samples. The staining was sometimes positive in the cells of the 
Bowman’s capsule, in the entire proximal convoluted tubule and affecting a deeper part of 
the cortex. The presence of positive tubules at the junction of the cortex and the medulla 
was frequent. Some representative pictures are shown in Figure 38. 
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Figure 38: Expression of KIM-1 by ISH in the kidney of PAN treated animals. In cortex (A) and 
(C), KIM-1 is increasing with treatment time in the damaged proximal convoluted tubule and 
also sometime in the parietal cells of the Bowmann’s capsule (day 14 only).  At the cortico-
medullary junction (B) and (D), KIM-1 expression is rare. Magnification x40 (A) (C) and x20 
(B)(D). Blue: NBT substrate for ISH; Red: counterstaining. 
 
 
The KIM-1 positivity as observed in these samples are showing a time dependent 
progression but also a spatial progression. As already mentioned, the first place where 
positive cells for KIM-1 are usually observed is in the descending portion of the proximal 
tubule and this location was interpreted as the most sensitive of the kidney. 
These time course results showed that there is an indirect tubular injury induced by PAN. 
Considering that PAN is a toxicant for the glomerulus, we can visualize with KIM-1 the 
downstream damages of the drug in the convoluted proximal tubule (segment S1) and the 
progression of the lesions that expand to the inner cortex until the segment S3 at the 
junction with the medulla. 
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Looking now at the cisplatin study samples, the KIM-1 expression was studied the same 
way, focusing on the location of KIM-1 positivity and looking how it relates to the treatment 
duration. 
The injury (assessed by KIM-1 positivity) is already started at day 3 with strong positivity 
observed in the descending portion of the proximal tubule at the cortico-medullary 
junction. Positivity in the cortex was rare except few isolated positive cells noticed until the 
lower part of the cortex.  
At day 7, there is a progression of the injury and positivity is found not only at the junction 
of cortex and medulla but became frequent until the outer cortex in many tubules. From 
day 14, the KIM-1 staining is generalized in all the cortex regions of the kidney. Most of the 
tubes expressing KIM-1 were strongly dilated. It gives the impression at this time point that 
the staining is regressing in some cells that seems to be degenerating cells.  
With this treatment, the KIM-1 expression is following a progression that starts in the cells 
of the descending convoluted tubule and then spread rapidly toward the outer cortex 
region. Compared to PAN treatment, the evolution of the positivity of KIM-1 is completely 
inverted, with an axis of progression from segment S3 until S1.  
The Figure 39 shows some representative animals that illustrate the observation. 
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Figure 39: Expression of KIM-1 by ISH in the kidney of Cisplatin treated animals. In cortex, (A) 
(C) (E) KIM-1 is increasing with treatment time in the damaged proximal convoluted tubule. 
At the cortico-medullary junction (B)(D)(F), KIM-1 expression is strong already at day 3. 
Magnification x40 (A)(C)(E) and x20 (B)(D)(F) (Blue: NBT substrate for ISH; Red: 
counterstaining). 
 
 
As the KIM-1 expression sounds to have a real differential spatial and temporal expression 
according to the treatment, the fingerprint approach was applied to this series of samples 
in order to standardize the dynamics. 
The overall pattern results are shown in Figure 40 for the PAN treatment and in Figure 41 
for treatment with cisplatin. It confirms that the staining is progressing in different area of 
the kidney in a time dependent manner. The axis of progression differs from one drug to 
the other and therefore indicates precisely the currently location of toxicity.  
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Figure 40: Fingerprint of KIM-1 expression after PAN treatment. Created  with Definiens. 
The cortex is represented in light grey; outer medulla in dark grey; inner medulla/pelvis in 
grey. The KIM-1 expression is represented in white color and appears as patchy signal 
increasing with time of treatment in the cortex mainly.  
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Figure 41: Fingerprint of KIM-1 expression after Cisplatin treatment. Created with Definiens. 
The cortex is represented in light grey; outer medulla in dark grey; inner medulla/pelvis in 
grey. The KIM-1 expression is represented in white color and appears as “ray” of signal 
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increasing with time of treatment.  
The quantification of the signal intensity in the different part of the kidney after PAN 
treatment (Figure 42), shows an absence of KIM-1 expression in any part of the organ at 
day 3 and until day 7. The signal intensity was very low and without any anatomic 
distinction between cortex and medulla. Instead at day 14, the signal for KIM-1 became 
strong particularly in the cortex region and the intensity of the signal is decreasing toward 
the medulla part. The treatment point of day 14 is clearly showing a differential expression 
pattern between the three segments. 
After treatment with Cisplatin, the spatial profile of KIM-1 is very interesting and strongly 
time dependent. In the segmented kidney (see Figure 43), the signal for KIM-1 in the inner 
medulla/pelvis segment is expressing very few KIM-1 after treatment and stays stable at 
any time point. In the opposite, the levels of KIM-1 in the outer-medulla are the first to be 
upregulated already at day 3 and dramatically increased at day 7. The Figure at day 14 
announces a reduction in the progression certainly associated to a degeneration of the cells 
and/or necrosis. In the cortex, the data shows a certain delay in this compartment compare 
to the others and this part is affected only in a second moment, progressing at day 7 and 
remaining more or less stable at day 14. 
We could illustrate that the expression of KIM-1 follows a clear dynamic and that PAN 
versus Cisplatin toxicity in the renal tubular cells can be discriminated by monitoring the 
location of KIM-1 expression.  
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Figure 42 and 43: Expression of KIM-1 in the segmented kidney (cortex, outer medulla, inner 
medulla)after treatment with PAN (top) and Cisplatin (bottom) for 3, 7 or 14 days. 
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Summary of the nephrotoxicant model results: tubular damage data 
The time course with the toxicants PAN or Cisplatin revealed a differential pattern of 
KIM-1 expression 
The topography of KIM-1 with PAN toxicity is starting from the convoluted portion of 
proximal tubule and progress toward the descending part.  
The induction of KIM-1 with the tubular toxicant Cisplatin is going in the opposite 
direction 
 
The pattern and spatial distribution of KIM-1 can be used to discriminate between  
primary and secondary tubular toxicity 
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4.19 In vitro studies using toxicant 
 
We were now interested to see if this differential expression is something that could be 
reproduced in vitro using a rat podocytes culture treated with the same toxicants. 
We decided to use and implement a rat primary isolated podocytes culture considering that 
no good quality cell line is available for this cell type and for this species. 
Isolation and primary culture of the rat podocytes was done accordingly to the improved 
method described by Katsuya K et al. in 2006 (Katsuya, Yaoita et al. 2006) and the details of 
the isolation and culture are given in the material method part. 
Before performing any experiment with the cells, the culture yield and performance had to 
be evaluated. According to the paper of Katsuya K et al., the number of isolated glomeruli 
expected from the perfusion of one rat should be around 20’000 glomeruli. This number 
was reached by us on several isolation tests and in some cases of optimal perfusion a 
maximum of 50’000 glomeruli could be obtained. From the cellular outgrowth, the 
expectations are around 600’000 purified podocytes according to the authors. From the in 
house results, this number was also found with some pick of 1’400’00 cells from one 
perfused rat. Also if these numbers are indicating a good implementation of the published 
method, this stays a culture method which is long and difficult. Running a treatment based 
experiment with different time point remains difficult and procurement of enough cells is a 
limitation to the method and number of experimental data. Therefore, our data have been 
generated from only one donor rat as all other experiments didn’t provide enough cells to 
test the two compound PAN and cisplatin at different time point. 
During the process of podocytes isolation, several microscopic examination steps were 
performed to verify the quality of the culture. The isolation and attachment of the glomeruli 
can be assessed at the first day after seeding by verifying the absence of tissue fragments or 
impurities. At day 4, the cellular outgrowth is visible around the glomeruli. After the re-
culture, isolated podocytes should be some large cells, branched, often binucleated and 
arborized. If this phenotype can be observed, some good mature podocytes were obtained. 
In the opposite, if some small, polygonal, cobblestone-like shape cells are observed, the 
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podocytes are dedifferentiated. An illustration of the different microscopic observations is 
shown in Figure 44. 
 
 
Figure 44: Picture of isolated glomeruli between day 1 and 4 (left), cellular outgrowth at day 
4 (middle) and isolated purified podocytes (right) 
 
By immunofluorescence, a specific staining for podocin and synaptopodin on purified 
podocytes was performed at day 1 after seeding. With the DAPI staining we could observed 
some binucleated cells as expected and with a very elongated shape. The signal for podocin 
was cytoplasmic and strong, when the staining for synaptopodin was membranous, less 
intense and was present on only elongated cells.  
Some rounded shape cells were also observed. These cells are not well attached yet and 
have foot process which is not developed for the moment (see Figure 45). Microscopic 
observation could not detect any contamination by other cells type like macrophage or 
mesangial cells. 
 
 Page 99 
 
Figure 45: Immunofluorescence on primary podocytes culture at day 1 using anti-podocin 
(green), anti-.synaptopodin (red) and Dapi (blue) as counterstaining. 
For a good morphological quality preparation, the cells were distributed in collagen type-I 
coated wells at a density of around 30’000 cells/well and were treated the next day for 3h, 
6h, 24h and 48h either with PAN or with Cisplatin. Most of the time points were done in 
triplicate. At the end of the experiment, total RNA was extracted for gene expression 
analysis. 
In a first approach, we merged the replicates and time points for each specific treatment 
(namely vehicle, cisplatin, PAN 0.1µg/ml and PAN 1µg/ml) in order to get an overall 
impression of the cells reactivity and behavior.  The parameters for the analysis were 
considering only the annotated probe sets and the transcripts with an absolute expression 
level over 50 (MAS 5.0). The fold change comparison was set with a minimum upregulation 
or downregulation fold change of 1.5 and data were fitted onto an ANOVA model with 
alpha at 0.05. 
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By applying these parameters, from the 31042 probe sets of the gene chip array, only 
13046 remaining probe sets had a correct annotation and/or didn’t fail the expression level 
filtering criteria. Within this selection, 128 probe sets had a fold change expression > 1.5 
compared to the vehicle group but many failed at the statistical ANOVA test. At the end, 
only 27 differentially expressed genes as compared to the vehicle group were considered 
statistically significant. 
From this low number of differentially regulated genes, the largest fraction appeared to be 
stress-related genes including heat-shock proteins or apoptosis related genes. We can 
already postulate of relatively weak effect of the drug on the culture. It means that either 
the drug concentrations applied were too low or the reactivity of the cells was weak and 
extremely variable. The complete list of regulated genes is available in Supplementary data 
part (Supplement data Table 4). 
Our two candidate genes Sema3G and Cst3 were not within the 27 significantly regulated 
genes. But looking at their global reaction, Sema3G is nevertheless showing a nice trend:  
there was no difference upon cisplatin treatment but instead PAN treatment is regulating 
down Sema3G in a dose dependent manner. None of the results were significant due to high 
standard deviation variations. The downregulation of Sema3G was not related to general 
cytotoxicity of the treatment agents as proven by the stability of the housekeeping gene 
Actb on the same samples. A general reactivity of the cell was also proven by looking the 
stress gene Hspa1a that was upregulated by both treatments Cisplatin and PAN. 
In the opposite of Sema3G, the global reaction of Cst3 instead was completely unrelated to 
both, treatment and dose.  
The graphical results of the earlier mentioned genes are shown in Figure 46. 
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Figure 46: Gene expression results for some selected genes after treatment of the rat 
podocytes culture with Cisplatin (50 µM) or PAN (0.1 or 1µg/ml). 
 
Independently from the fold change analysis, a supervised analysis was performed. Each 
signature was built on previous knowledge to verify the specificity of the culture, the 
potential contamination of the culture, the pathological stage and to follow the reaction of 
the gene of interest over time. 
The selection of podocytes specific gene was chosen from literature (Katsuya, Yaoita et al. 
2006, Patrakka and Tryggvason 2010) as well as the selection of pathological activation 
genes, endothelial cells markers and mesangial cells markers. Average expression levels 
expressed as a “score” for the different gene signatures were derived for untreated 
podocytes compared to treated cells at the different time points. In addition, two different 
comparators were used; (i.) a normal whole kidney sample and (ii.) samples from laser 
capture micro-dissected glomeruli (the same samples as for the identification of glomeruli 
specific genes). 
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The details of the gene list are described below: 
Gene list for podocytes specific genes 
Probe Set Gene Symbol Gene 
1395337_at Tjp1 tight junction protein 1 
1388786_at Synpo synaptopodin 
1369895_s_at Podxl podocalyxin-like 
1369695_at Wt1 Wilms tumor 1 
1368412_a_at Ptpro protein tyrosine phosphatase, receptor type, O 
1370081_a_at Vegfa vascular endothelial growth factor A 
1369942_at Actn4 actinin alpha 4 
1367681_at Cd151 CD151 molecule (Raph blood group) 
1389282_at Itga3 integrin, alpha 3 
1380537_at Nckap1l NCK associated protein 1 like 
1388177_at Ddn dendrin 
1369153_at Nphs1 nephrosis 1, congenital, Finnish type (nephrin) 
 
Gene list for endothelial cells  
Probe Set Gene Symbol Gene 
1371545_at Pecam1 platelet/endothelial cell adhesion molecule 1 
1389234_at Vwf von Willebrand factor 
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Gene list for mesangial cells contamination 
Probe Set Gene Symbol Gene 
1369652_at Thy1 Thy-1 cell surface antigen 
1375010_at Cd68 Cd68 molecule 
1369651_at Thy1 Thy-1 cell surface antigen 
 
Gene list for impaired podocytes 
Probe Set Gene Symbol Gene 
1369640_at Gja1 gap junction protein, alpha 1 
1367600_at Des desmin 
1372002_at Gja1 gap junction protein, alpha 1 
 
 
The podocytes specific gene list tells us about the characteristics of the cells during the 
culture time. All the tested genes were well expressed in the primary podocytes culture at a 
much higher level than a whole kidney sample, indicating an enrichment of the podocytes 
specific genes in these samples. This tells us that the isolation method of podocytes 
performed well and that the culture was of good quality. Nevertheless, two genes from the 
gene list tested, namely nephrin and dendrin had a very low expression level compared to 
normal kidney and isolated glomeruli. In fact, this reproduce the observation already done 
by Katsuya et al. (Katsuya, Yaoita et al. 2006) and can be explain by the fact that nephrin is 
a marker of the slit diaphragm. The cultured cells didn’t reach this maturation step and 
were not able to develop such specific and elaborate filtration structure in vitro. Excluding 
these two genes, the podocyte gene list score in cultured cells reached higher levels than 
observed for the isolated glomerulus sample. The Figure 47 is showing the scoring results 
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of the podocytes specific genes in the culture compared to kidney and glomeruli with and 
without the Nphs1/dendrin genes. 
 
 
 
Figure 47: Gene expression results for podocytes specific genes in the untreated culture at 
different time points. The values represent the geometric mean of the fold change between 
any treatment group and whole kidney, for all genes in the list. Top: gene list with Nphs1 and 
dendrin. Bottom: gene list without Nphs1and dendrin. 
 
The cultured podocytes were also scored for the presence of endothelial cells and 
mesangial cell contamination: no changes for endothelial cells could be detected in the 
culture as well for mesangial cells until 24hours. At 48h, the level of mesangial/fibroblast 
genes has been found to be suddenly increased and could indicate some proliferation of 
these cells in the culture. The time point of 48 hours has been removed for further analysis 
(Figure 48 and 49). 
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Figure 48: Contamination of the culture by mesangial cells, as indicated by increased 
expression scores in a gene list specific for this cell type, is appearing after 48 hours of culture. 
 
 
Figure 49: Absence of contamination of the culture by endothelial cells, as indicated by 
negative expression scores in a gene list specific for this cell type, compared to whole kidney. 
 
The next gene list was built around pathological markers and the results showed an 
increase of these markers in the cultured cells. These signs of abnormality are related to 
an in vitro context and are also in agreement with the results of Katsuya et al. method 
(Figure 50) 
 
Figure 50: Scoring results for markers of impaired podocytes in culture, compared to whole 
kidney. 
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Finally, the analysis of the raw expression levels of Sema3G and CYTC transcripts in the 
untreated cells revealed a good and relatively stable expression level for CYTC in the 
culture. Instead, the levels of Sema3G transcripts are very low and tend to decline with the 
culture duration, indicating that the culture conditions are rapidly affecting the expression 
of this marker (Figure 51). 
 
  
Figure 51: Expression levels of Sema3G and Cst3 in untreated culture of podocytes compared 
to whole kidney 
 
The scoring results of Sema3G expression in podocytes culture after treatment with 
Cisplatin revealed that there is no treatment effect on this gene in podocytes. Cisplatin 
treated samples showed a decreasing expression of Sema3G at exactly the same kinetics as 
in the untreated cells. 
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To the contrary, when the cells are treated with PAN, we can observe a dose dependent and 
a time related response. The response at 3hours is minimal with similar levels of Sema3G 
expression at low and/or high dose of PAN.  But after 6hours of culture, the PAN treated 
cells showed an accelerated decreased of Sema3G in a dose dependent manner. The results 
at the time point of 24hours are even more marked (Figure 52). Unfortunately none of 
these results are statistically significant due to high variation and thus represent just a 
trend. 
 
 
 
Figure 52: Sema3G expression in podocytes after treatment with Cisplatin (top graph) and 
PAN (0.1 and 1µg/ml) (bottom graph). Results are expressed in fold change compare to 
vehicle treatment at 3 hours.  
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The scoring results for CYTC expression after treatment with Cisplatin showed a negative 
expression score which do not reflect any specific effect considering that Cisplatin is a 
tubular specific toxicant and was used as negative control on the podocytes cells. It mays 
just show a general cytotoxic effect on the culture even if the dosage selected should not.  
But also with the treatment of the cells with PAN, CYTC was expected to be upregulated 
based on the in vivo data and surprisingly no drug specific effects were seen, without time 
related effect (see Figure 53). The expressions of CYTC stays stable in the cells until 6 hours 
and suddenly dramatically fall down at 24hours.   
 
 
Figure 53: CYTC expression in podocytes after treatment with Cisplatin or PAN (0.1and 
1µg/ml)  
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Summary of the nephrotoxicant model results: in vitro data 
A primary culture of rat podocytes could be established and tested for toxicity reaction 
with PAN and cisplatin.  
Overall, very few genes were affected by the treatment. 
 
Sema3G was down regulated in vitro in a dose and time dependent manner mirroring 
the in vivo findings 
The results were not statistically significant and could be interpreted only as a trend. 
 
The second marker CYTC didn’t reproduce the in vivo figure. 
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4.20 Comparative summary of the animal models results 
 
The results for the expression of Sema3G, CYTC and KIM-1 in the different animal models 
are summarized in the Table 5. The in vitro results for Sema3G and CYTC are summarized 
in Table 6. 
This summary gives an overview of the reactivity of these 3 markers assessed in different 
situation of podocyte adaption and injury and shows that each marker had a different 
reactivity according to the type and/or the intensity of the injury. 
 
Table 5 (Top): Summary of the in vivo results and Table 6 (Bottom): Summary of the in vitro 
results (Legend: + or – refer to expression; ↓or ↑ refer to down and up regulation). 
In vivo Model / type Podocytes Sema3G CYTC KIM-1  
outer 
medulla 
KIM-1  
cortex 
Normal kidney Healthy + + _ _ 
Albumin overload 
Functional model 
No injury + + + ++ 
PHN 
Structural model 
(alteration of GBM) 
Stress leading to 
podocyte adaption  
(reversible injury) 
↓ + + - 
PAN 
Glomerular toxicity 
model 
Toxicity leading to 
podocyte injury 
 
↓↓ ↑↑↑ + +++ 
Cisplatin  
Tubular toxicity model 
No podocyte injury + + +++ ++ 
 
In vitro model 
Primary rat podocytes 
Sema3G CYTC 
Untreated - + 
PAN 0.1µg/ml ↓ ↓↑ 
PAN 1 µg/ml ↓↓ ↓↑ 
Cisplatin - ↓ 
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6. Discussion 
 
The goal of these investigations was to identify podocytes specific markers that could be 
used to characterize and differentiate early podocyte adaption (reversible injuries) from 
podocyte irreversible injury. Furthermore we wanted to verify the possible integration of 
these podocytes markers with a tubular injury marker in order to define patterns of tissue 
injury.  The hope is to use this pattern of injury to identify early signs of glomerular 
dysfunction/damage in toxicology studies, preclinical models of diseases and possibly 
clinical case series.  After experimental validation, this pattern could be applied in drug 
discovery and development to better characterize early glomerular toxic injury and 
support the development of new drugs. Depending of translatability to human, this injury 
pattern may be considered for potential clinical application and an improved evaluation of 
glomerular diseases. 
 
To reach the goal we started by identifying podocytes specific markers, tested them in 
different animal models of podocyte injury, and integrate these markers with a well-known 
tubular injury marker, KIM-1, to define the different patterns of nephron injury. The 
genomic analysis of laser captured microdissected glomeruli identified Sema3G and CYTC 
as potential interesting candidates. Using molecular localization, we demonstrated that the 
expression of these markers in the glomerulus is podocyte specific. We also proved that 
Sema3G expression is specific to the podocyte in glomeruli for several other species, 
including human. CYTC expression in podocytes is instead rat specific, or below the level of 
detection by IHC.  
By testing the expression of Sema3G in different models of podocyte stress and injury, we 
found that Sema3G was down-regulated in the model of PHN and drug-induced toxicity 
with PAN. These models are representing situation of podocyte adaption and damage, 
respectively. On the other hand, Sema3G expression remains unchanged in a model of 
albumin overload which with the protocol used, represent a reversible functional alteration 
without podocyte injury. In addition, Sema3G expression did not vary in a model of tubular 
toxicity induced by cisplatin. In conclusion, Sema3G is downregulation in case of both 
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reversible and irreversible injury but not in case of functional impairment without injury. 
 
In the opposite, the marker CYTC normally expressed by the podocytes of the rat, was 
upregulated only upon PAN toxicity but not in models of albumin overload and PHN. 
Therefore we conclude that the upregulation of CYTC potentially represent a marker of 
irreversible podocyte injury. 
 
4.21 Sema3G as marker of podocyte adaption and injury 
 
Sema3G has been mainly studied for its autocrine effect on endothelial cells and its 
paracrine effect on smooth muscle cells (Kutschera, Weber et al. 2011),  as well as for its 
function as repulsive axon guidance signalling molecule (Yu and Moens 2005) .  In our 
studies, we found expression of Sema3G and its receptor NRP2 in the endothelial cells of 
the kidney cortex vascular bed, as expected by their known expression and function in the 
endothelial cells. However, Sema3G was absent in the endothelial cells of the glomerulus 
but present at high levels in the specialized epithelial cells. The presence of Sema3G in the 
podocytes represents a new finding.  
At the moment, the significance of Sema3G expression in podocyte is not clear. Considering 
Sema3G function as repulsive axon guidance signalling molecule, it may be secreted by the 
podocytes in the Bowman’s space and interact with NRP2 present on the parietal cells of 
the Bowman’s capsule (vis-à-vis the podocyte). Sema3G could act as a repulsive signalling 
molecule helping to maintain the appropriate distance between the parietal layer and 
visceral layer of the capsule. 
In addition to this potential function to maintain the Bowman’s capsule space, Sema3G 
could be implicated in the maintenance of the glomerular filtration barrier and/or in 
podocyte protection, together with VEGF. In fact NRP2 is not exclusively binding Sema3G 
but is part of the entire complex of NRPs–plexins receptor family, which also binds VEGF 
(Schramek, Sarkozi et al. 2009). High expression levels of VEGF are present in the 
 Page 113 
podocytes and are playing a key role for the establishment and maintenance of the 
glomerular filtration barrier (Eremina, Sood et al. 2003, Eremina, Baelde et al. 2007). The 
podocyte is responsible to provide migratory cues to glomerular endothelial cells to 
establish the renal filtration barrier and because VEGF is still expressed by mature 
podocytes, it is often considerer to play this role. VEGF has been also suggested to function 
in an autocrine fashion that is required for podocyte survival and that podocyte survival is 
diminished upon inhibition of VEGF receptor (Foster, Hole et al. 2003). Similarly to 
Sema3G, the expression of VEGF has been shown to be down regulated in podocytes upon 
treatment with PAN in the rat kidney (Fan, Wakayama et al. 2002). Therefore it is entirely 
possible that the presence of Sema3G in podocytes may be involved in similar processes. 
Sema3G could represent a redundant or a synergic molecule to VEGF that insure a function 
in the maintenance of the filtration barrier and/or podocyte protection. 
Very recently, Sema3G has also been described as a novel podocyte expressed gene which 
protects the podocyte from inflammatory kidney disease and diabetic nephropathy 
(Ishibashi, Takemoto et al. 2016). These data confirm our findings on Sema3G podocyte 
expression and reinforce the potential importance of this molecule in podocyte biology.  
The authors have demonstrated a role for Sema3G as inhibitor of basal inflammatory 
cytokine expression through the ERK and NF-kB signaling, acting therefore as kidney 
inflammation protector. 
Our results suggest that Sema3G downregulation represent a general marker of podocyte 
stress while its expression remains unchanged without podocytes adaption or injury. 
During the heterologous phase of the PHN model, the podocytes are lifted from the 
glomerular basal membrane by the deposition of anti-FxA1 antibodies and stimulated by 
the deposition of complement. We hypothesize that this indirectly a source of cellular 
stress and the podocyte start repressing Sema3G mRNA expression. PAN is causing direct 
toxic injury and we see repression of Sema3G expression concomitantly with the 
morphological alteration of the podocytes. 
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On the opposite, in presence of a functional impairment (reversible injury) where the 
podocyte is undamaged, the podocytes remains able to maintain Sema3G expression. These 
results based on in vivo model were also confirmed in vitro using a primary culture of rat 
podocytes. After treatment with toxicants, a time and dose dependent decrease of Sema3G 
could be reproduced while its expression remains unchanged after Cisplatin treatment.  
In the literature, Sema3G itself has never been associated to podocyte stress or injury. But 
in diabetic nephropathies which are also associated to podocytes adaption/injury and 
proteinuria, some data showed that the expression of both isoforms of neuropilin receptor 
(NRP1 and NRP2) as well as the entire signaling complex involving another Semaphorin 
family member, semaphoring-3A is significantly reduced in the context of this pathology 
(Bondeva, Ruster et al. 2009).  
In summary, our work demonstrates that Sema3G downregulation is a valuable marker of 
podocyte injury, allowing to discriminate irreversible injuries due to structural damage 
and/or toxic damages from reversible podocytes injury. Furthermore the specific 
expression of Sema3G in podocytes of several species, as demonstrated earlier in this work, 
warrant future investigations to assess its potential as podocyte injury markers in human 
diseases. 
 
4.22 Cystatin C as marker of podocyte injury  
 
The second podocyte specific marker assessed in this study, Cystatin C, was also localized 
in the rat kidney and was shown to be highly expressed in podocytes at the mRNA as wells 
as at the protein level. This indicates that, on the contrary of what was described so far, 
podocytes are an intrarenal source of cystatin C. This implies that cystatin C could have a 
function in these cells. 
The result of the CYTC expression in podocyte injury models seems in relation to podocyte 
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injury only. This was demonstrated by the time dependent increase of CYTC expression 
upon PAN treatment. The increase of CYTC compared to Sema3G downregulation 
strengthens the Sema3G results. In fact, it confirms that the reduction of Sema3G in the 
same sample is the result of an active cellular process in relation to podocyte injury, and 
not a general toxic effect of the PAN treatment on podocytes. The final outcome of these 
investigations is that the expression of CYTC is modulated in vivo only in case of podocyte 
toxicity but not in case of functional impairment (albumin overload model) or structural 
impairments (PHN model). Therefore we conclude that the modulation of CYTC is 
restricted to situations with major morphological changes of the podocyte (e.g. podocytes 
effacement due to cytoskeleton changes) and cell death induced by the toxic effect of PAN. 
When the podocytes are injured due to toxicants, the most characteristic change observed 
is the reorganization of actin skeleton that leads to foot process effacement. Within many 
others, one cause of foot process effacement is the activation of the cathepsin L-mediated 
proteolysis and more generally an enzymatic cleavage of essential podocytes actin 
dynamics by cytosolic cathepsin-L (Mundel and Reiser 2010). The increase of the protease 
inhibitor CYTC observed in podocytes could be a reaction to limit and/or compensate the 
cathepsin-L activity and avoid or reduce proteinuria.  
The function of CYTC is not limited to protease inhibition activity only and CYTC can be 
regulated by several stimuli and is susceptible to chemical insult. The roles of CYTC as a 
disease-associated protein, subjected to multiple regulations,  has recently been reviewed 
(Xu, Ding et al. 2015). In this review, the authors linked CYTC to several pathological 
processes through various mechanisms, independently from its function as protease 
inhibitor.  
As example, some very high levels of CYTC are present in brain of patients with epilepsy, in 
animal models of neurodegenerative conditions and in response to injury. It was 
demonstrated in mouse cortical neurons that CYTC plays a protective role by inducing 
autophagy and is neuroprotective in neurodegenerative diseases (Tizon, Sahoo et al. 2010). 
Now, the podocyte is a cell that exhibits an unusually high level of constitutive autophagy 
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(Hartleben, Godel et al. 2010) and share this specificity with the neuronal cells. Knowing 
that the cellular response to stress through autophagy has been identified as a major 
pathway to maintain cellular homeostasis, the autophagy regulation into these two cells 
types is crucial and could be an important task for CYTC in the podocytes of the rat. The 
induction of autophagy by CYTC in podocytes has not been demonstrated yet but need 
further investigations.  
In summary, our data indicate that CYTC, independently from its function, is a specific 
marker of podocyte toxic injury only and not of functional (albumin overload model) or 
structural impairments (PHN model) of podocytes.  
Unfortunately, our data cannot currently address the potential use of CYTC as marker of 
podocyte toxicity in other species. The basal expression of CYTC in podocytes seems to be 
rat specific, but this does not means that following exposure to specific toxicants, the 
podocytes of other species could start expressing CYTC or increase the expression up to 
levels detectable by in situ hybridization.  
 
4.23 A tubular injury marker associated to podocyte injury evaluation 
 
When the podocytes are injured, the foot processes simplify or lose their normal 
interdigitating pattern and the slit diaphragm is disrupted. With a damaged filtration 
barrier, some high molecular weight proteins are reaching the proximal tubule and are 
damaging the cells. Considering that the protein KIM-1 is localized in the apical brush 
border of the proximal tubule cells and is a very sensitive indicator of many type of tubular 
injury (Ichimura, Bonventre et al. 1998, Bailly, Zhang et al. 2002), including protein 
overload  (van Timmeren, Bakker et al. 2006), KIM-1 can be expected to react to all the 
situations of barrier impairment  tested in this work. 
KIM-1 increased expression in response to a tubular toxicant like Cisplatin is well-known. 
Independently from his well-known role as tubular injury biomarker measurable in the 
urine, KIM-1 can also be use at the mRNA level as tissue biomarker for detection of early 
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injury events in the proximal tubule cells. Having the possibility to study KIM-1 localization 
during a time course study with a tubular toxicant, can give a sequential picture of toxicity 
McDuffie and colleagues (McDuffie, Ma et al. 2013) studied the time course of renal 
proximal tubule injury following cisplatin administration but focused more on the 
correlation of temporal expression versus the histopathology and urinary biomarker. The 
spatial distribution in tissue was not evaluated. 
Therefore, we investigated the spatial expression of KIM-1 to verify where its upregulation 
starts and how it evolves along the proximal tubule in relation to treatment time. With this 
approach, we were able to identify a pattern of spatial progression along the proximal 
tubule. In fact, it appears that KIM-1 expression follows precisely the drug toxic effect along 
the proximal tubule, starting from the descending portion of the proximal tubule (S3) 
which is the most sensitive portion of the tubule to injury and over time is expanding 
toward the convoluted part of the proximal tubule (S1). This expression pattern follows the 
accumulation of Cisplatin in the proximal tubule by organic cation transporter uptake 
(Pabla and Dong 2008). Our results show that KIM-1 is a good indicator of the topography 
of injury related to Cisplatin toxicity. In our hands KIM-1 in situ hybridization created a 
visual pattern of tubular toxicity reflecting the spatial and temporal progression of the 
lesions. This work demonstrated the validity of KIM-1 spatial localization as a method to 
follow toxicity along the tubule in a case of primary tubular toxicity.  
As next step we proceed testing the spatial localization of KIM-1 as indicator of secondary 
tubular injury associated to a podocyte “primary” injury. We reasoned that if the podocyte 
is the primary target of an injury located at the beginning of the nephron, the proximal 
tubule will indirectly suffer and should show some “secondary” injury. When assessing 
KIM-1 expression in the time course study with PAN treatment, we were able to detect 
KIM-1 positivity in the proximal tubule and in the parietal epithelium of Bowman’s capsule 
before detecting KIM-1 in the descending portion. The fingerprint analysis and 
quantification reflects perfectly this pattern with KIM-1 expression starting first in the 
cortex region in a patchy way. It reveals a feature completely different from the one 
observed with the sample in the Cisplatin study. In fact, our results are in keeping with the 
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description of KIM-1 expression in glomeruli of a rat diabetic model (Zhao, Zhang et al. 
2011), where the authors demonstrated a correlation between the level of glomerular KIM-
1 expression and the degree of proteinuria, proving that KIM-1 is a sensitive marker that 
correlate with the extent of loss of podocytes differentiation markers in the damaged 
glomeruli. These results demonstrate that KIM-1 can also be used as a local tissue marker 
of injury, independently from the cause of the injury (glomerulus versus tubular). The 
observation of KIM-1 positivity either in parietal epithelia cells of the Bowman’s capsule, in 
the proximal epithelial cells directly after the glomeruli or in the descending portion of the 
proximal tubule, can help to understand the site of initiation of toxicity and its evolution.  
Looking now at the animal models non related to drug-induced injury, it appears 
interestingly that a pattern of KIM-1 expression similar to the PAN model was observed in 
the case of albumin overload, while KIM-1 expression in the PHN model was much lower 
(almost undetectable) but more similar to Cisplatin pattern.  These differences are 
probably reflecting the filtration barrier capacity of the glomerulus and the consequent 
injury related to the flow of protein. From the functional point of view, the albumin 
overload model determines a stronger functional impairment of the filtration barrier 
capacity of the glomerulus and higher flow of protein in the tubule inducing injury than the 
PHN model. 
 
4.24 A pattern of tissue injury to explore glomerular damages? 
 
Podocyte stress and/or injury is not a phenomenon that can be assessed  using a single 
marker and as recently reviewed by Braun et al. in 2016  (Braun, Becker et al. 2016), there 
are long-standing debate on the underlying mechanisms responsible for podocyte 
depletion, ranging for necrosis and apoptosis to detachment of viable cells from the 
glomerular basement membrane.  
Viable podocytes can be isolated from the urine of healthy as well as glomerular disease 
samples (Vogelmann, Nelson et al. 2003) and represents an interesting source of 
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information. Many approaches are attempting to take advantage of these isolated cells to 
characterize and evaluate podocyte injury. As example Sato et al. (Sato, Wharram et al. 
2009) monitored podocyte loss by detecting nephrin and podocin mRNA in urine of 
diaphtheria toxin receptor transgenic rat and consider that it could be a useful clinical tool 
for diagnostic and monitoring of glomerular diseases. Using the same strategy , Lioudaki 
(Lioudaki, Stylianou et al. 2015) measured the presence of mRNA for podocin,  nephrin and 
synaptopodin in urine of patients with diabetes mellitus (DM) and demonstrate that DM is 
the only significant determinant of the presence of nephrin and/or podocin mRNA in urine 
in this population.  
Our goal is different from these efforts and we are not attempting to develop accessible 
biomarkers to identify podocytes specific injuries. The goal of our research is to develop 
tissue markers able to discriminate different categories of podocytes injuries, to 
understand transient versus permanent injury, and through the use of a tubular damage 
marker, the consequences in terms of filtration impairment.  It is the integration of these 
different markers together (and not from the analysis of each of them separately) that 
generate an added value in understanding the consequences on the kidney functionality. 
The proposed combination is composed of  a molecule (Sema3G) that reflect the podocyte 
injury level, with the expression of CYTC that indicate situations of morphological changes 
(e.g. podocytes effacement due to cytoskeleton changes), with finally a third marker (KIM-
1) helping to determine the toxic effect on tubule resulting from podocyte injury and 
consequent flow of protein.  
By testing this combination of markers in several model of injury, we revealed a differential 
expression pattern specific to each injury type and/or effect on glomerular protein 
filtration: 
 The functional impairment of podocytes (absence of adaption or injury) is 
characterized by an absence of modulation of the podocyte markers although 
tubular injury is present due to the excessive flow of proteins in the tubule. 
 The podocytes adaption (structural impairment of GBM) is characterized by a 
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specific downregulation of Sema3G and is accompanied by a weak tubular injury.  
 The podocytes injury (drug-induced toxicity) is characterized by a downregulation 
of Sema3G and an upregulation of CYTC accompanied by a strong tubular injury 
similar to functional impairment toxicity.  
The classification detailed above demonstrate that the combination of these 3 markers 
represents a valuable tool for determining effect of drugs or diseases, on  podocyte 
integrity and the consequences on  tubular functions.  
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7. Future outlook 
 
This work could identify useful podocyte markers and could demonstrate that combining 
in-situ glomerular and tubular injury markers enables a more, sensitive detection of 
podocyte injury. 
This combination of markers can be used for direct toxicity assessment on podocytes in 
investigative rat toxicology study. Detection of the two markers Sema3G and CYTC on 
tissue sections is complementary to classical clinical pathology and urinary biomarker and 
will contribute to their interpretation. This will provide information about the “degree” of 
injury of the podocyte. By localizing KIM-1 direct or indirect tubular toxicity of the drug 
compound can be predicted. 
Furthermore, such a combination of markers can be applied to animal models of kidney 
disease, as screening tool for drug selection. Hence, it can also be used as a 
pharmacodynamic readout of drug efficacy. 
An interesting aspect to further explore would be the reversibility of the Sema3G 
downregulation. In the present studies, all animal models were assessed during the 
treatment period no recovery arm were included in the study design. Normalization of 
Sema3G expression levels would imply that podocytes have a certain capacity of 
regeneration. As proliferation of podocytes is very unusual in the majority of the 
glomerular diseases, the remaining adult podocytes are unable to replace the depleted or 
injured ones. However, parietal epithelial cells are often proposed as potential progenitors 
for podocytes but also the Cells of Renin Lineage (CoRL) exhibit marked plasticity (review 
of (Shankland, Pippin et al. 2014) giving some hope of potential restauration.  
Equally interesting it will be to further explore reversibility of KIM-1 downregulation 
during a recovery phase. It was shown, in a case of adriamycin-induced nephropathy 
(Kramer, van Timmeren et al. 2009), that KIM-1 downregulation was reversible and 
proportional to proteinuria reduction indicating reversibility of early tubular injury. 
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Expression of Sema3G and CYTC in podocytes of other species has been assessed in mouse, 
dog and monkey by in-situ hybridization. The presence of Sema3G in other species opens 
perspective for applying this marker as screening marker for podocytes injury. As 
glomerulonephritis in dogs and cats have been clearly described (Slauson and Lewis 1979), 
measurement of Sema3G expression in podocytes in these species could guide to 
discriminate between immune versus non-immune glomerulopathies and improve the 
diagnosis as well as guide therapy. 
Finally, the ultimate goal would be assess Sema3G expression in different types of human 
glomerulus pathology and investigate if the animal models results could be translated. 
In summary, the markers explored in the present work give very precise and local 
information about the sequence of the pathological events, starting at the level of the 
glomerulus in the podocyte cells and extending to the tubular cells injury. Overall, this will 
contribute to further elucidate the pathogenesis of glomerulopathies. 
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8. Conclusion 
 
The maintenance of the glomerular filtration barrier integrity is a mandate for the proper 
functionality of the kidney and podocyte injury is playing a central role in kidney 
dysfunction. 
Two novel markers Sema3G and CYTC highly expressed in podocytes could be identified 
and tested in several type of podocyte injury (e.g. functional or structural impairment and 
drug-induced toxicity) and showed some differential expression according to the type and 
intensity of the injury. In combination with the tubular injury marker KIM-1, an integrated 
tissue injury pattern tool could be proposed. 
As each member of this panel of markers has a different behavior according to the type of 
podocyte injury, it became possible not only to identify earlier podocyte injury but also to 
describe the sequence of the injury events, including the indirect toxicity related to the 
protein outflow into the proximal tubules. 
Such a panel of markers requires the availability of tissue section or biopsy but has the 
advantage to give an “in situ” picture with a resolution at the cellular level. 
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9. Supplementary data 
 
Supplementary data Table 1: Primer sequences for Sema3G, CYTC and KIM-1 riboprobes 
generation. 
 
Gene 
name 
Accession 
number 
Forward primer sequence Reverse primer sequence Amplicon size  
and position 
Rat 
Sema3G 
NM_001100882 GGCTCAGCCGCCTTGAT CGAAACCAGTGAGCTGAAGGAT 219 bp 
(1968-2186) 
Rat  
Cst3 
NM_012837 CTCCGCAGGAGGCAGATG ACAAGTAAGGGACCATTGGC 371 bp 
(164-535) 
Rat 
KIM-1 
NM_ 173149 TTGCCCTCATAGATAAGTAGAAGAAGAG GAAGGAAACCCGTGGTAGTCC 401 bp 
(1992-2392) 
Mouse 
Sema3G 
NM_001025379 GACGCAGGAAACTACACTTGCA CCCGTGAGCTGAAGGATGTC 200 bp (1983-
2182) 
Mouse 
Cst3 
NM_009976 CGCTGTGAGCGAGTACAACAA CAGGGAGTGTGTGCCTTTCC 241 bp   
(282-531)       
Dog 
Sema3G 
XM_541852 CCGACCAGGTAAAGACAGATGAG TGCGCCCGGCTCTTC 
 
406bp   
(1958-2363) 
Dog 
Cst3 
XM_003639821 ACAACCGGGCGAGCAA TCTGGAAAGAGCAGAGCGTTTT 200 bp  
(327-527) 
Human 
Sema3G 
NM_020163 TCGAGGTGTACGCGCTGTT CAGGAAAATGACATCGTAGGTCC 401bp (1026-1427) 
Human 
Cst3 
NM_000099 
 
CCTGGTGGGAGGCCCCATGGACG GTGCATAAGAGGTGATAGGC 383 bp  
(288-671) 
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Supplementary data Table 2: Detailed probes concentrations and hybridization conditions 
 
Probe name Probe quantity/ per slide Hybridization temperature Stringency wash conditions 
Rat Sema3G 20ng 65°C 3 times 2xSSC at 60°C 
Rat Cst3 2ng 65°C 3 times 0.1xSSC at 70°C 
Rat KIM-1 20ng 65°C 3 times 0.1xSSC at 70°C 
Mouse Sema3G 50ng 65°C 3 times 2xSSC at 60°C 
Mouse Cst3 50ng 70°C 3 times 2xSSC at 65°C 
Dog Sema3G 50ng 70°C 3 times 2xSSC at 65°C 
Dog Cst3 50ng 65°C 3 times 2xSSC at 60°C 
Monkey Sema3G (using the 
human probe) 
150ng 65°C 3 times 2xSSC at 60°C 
Monkey Cst3 (using the 
human probe) 
50ng 70°C 3 times 2xSSC at 65°C 
Human Sema3G 75ng 55°C 3 times 2xSSC at 50°C 
Human Cst3 50ng 65°C 3 times 2xSSC at 60°C 
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Supplementary data Table 3:  Gene list of the gene expression analysis results from laser 
capture microdissected glomeruli versus cortex without glomeruli 
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1367562_at Sparc 
secreted protein, acidic, 
cysteine-rich 
(osteonectin) 3181 14589 4.59 13.83 2.20 4.59 
1.04E-
05 
96107.
418 
1391856_at Sema3g 
sema domain, 
immunoglobulin domain 
(Ig), short basic domain, 
secreted, (semaphorin) 
3G 777 11138 14.33 13.44 3.84 14.33 
9.24E-
06 
108238
.947 
1369895_s
_at Podxl podocalyxin-like 1011 10732 10.61 13.39 3.41 10.61 
3.79E-
06 
263651
.824 
1370855_at Cst3 cystatin C 1276 10373 8.13 13.34 3.02 8.13 
0.0001
039 
9628.0
55 
1393368_at Osbpl5 
oxysterol binding 
protein-like 5 1050 8367 7.97 13.03 2.99 7.97 
1.29E-
05 
77584.
571 
1368412_a
_at Ptpro 
protein tyrosine 
phosphatase, receptor 
type, O 343 7849 22.90 12.94 4.52 22.90 
6.37E-
06 
156969
.239 
1388786_at Synpo synaptopodin 696 6705 9.64 12.71 3.27 9.64 
7.59E-
05 
13170.
219 
1385788_at Ephb3 Eph receptor B3 603 6232 10.33 12.61 3.37 10.33 
0.0027
464 
364.10
8 
1387146_a
_at Ednrb 
endothelin receptor type 
B 898 6023 6.71 12.56 2.75 6.71 
6.78E-
06 
147522
.735 
1398827_at Cd81 Cd81 molecule 918 5535 6.03 12.43 2.59 6.03 
0.0001
567 
6381.1
22 
1398333_at Epas1 
endothelial PAS domain 
protein 1 1301 5518 4.24 12.43 2.08 4.24 
2.65E-
05 
37696.
577 
1381548_at Golim4 
golgi integral membrane 
protein 4 677 5395 7.97 12.40 2.99 7.97 
0.0003
924 
2548.1
26 
1390119_at Sfrp2 
secreted frizzled-related 
protein 2 389 4874 12.52 12.25 3.65 12.52 
4.08E-
05 
24500.
828 
1385823_s
_at Podxl podocalyxin-like 223 4809 21.54 12.23 4.43 21.54 
0.0001
367 
7316.0
18 
1367568_a
_at Mgp matrix Gla protein 1030 4777 4.64 12.22 2.21 4.64 
1.36E-
06 
734485
.145 
1384509_s
_at Pcdh17 protocadherin 17 722 4715 6.53 12.20 2.71 6.53 
0.0003
773 
2650.1
68 
1385243_at Maf 
v-maf avian 
musculoaponeurotic 
fibrosarcoma oncogene 
homolog 995 4346 4.37 12.09 2.13 4.37 
0.0007
528 
1328.3
37 
1367816_at Hopx HOP homeobox 339 4185 12.34 12.03 3.63 12.34 
5.90E-
05 
16944.
945 
1367574_at Vim vimentin 683 4143 6.06 12.02 2.60 6.06 
0.0002
56 
3906.8
09 
1369008_a
_at Olfm1 olfactomedin 1 154 4070 26.39 11.99 4.72 26.39 
0.0001
666 
6002.7
42 
1370254_at Clic5 
chloride intracellular 
channel 5 247 4065 16.49 11.99 4.04 16.49 
0.0001
265 
7902.9
48 
1373657_at Slc31a2 
solute carrier family 31 
(copper transporter), 
member 2 677 4059 6.00 11.99 2.58 6.00 
0.0014
231 
702.71
3 
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1368860_at Phlda1 
pleckstrin homology-like 
domain, family A, 
member 1 419 3997 9.55 11.96 3.26 9.55 
0.0007
331 
1364.0
85 
1368858_at Ugt8 
UDP glycosyltransferase 
8 481 3905 8.12 11.93 3.02 8.12 
6.03E-
06 
165832
.443 
1385540_at Pias1 
protein inhibitor of 
activated STAT, 1 939 3764 4.01 11.88 2.00 4.01 
1.18E-
05 
84581.
369 
1369961_at Ppap2a 
phosphatidic acid 
phosphatase type 2A 502 3706 7.38 11.86 2.88 7.38 
9.39E-
05 
10648.
246 
1367948_a
_at Kdr 
kinase insert domain 
receptor 644 3692 5.73 11.85 2.52 5.73 
5.06E-
05 
19774.
191 
1372299_at Cdkn1c 
cyclin-dependent kinase 
inhibitor 1C 278 3662 13.18 11.84 3.72 13.18 
3.04E-
05 
32849.
347 
1368842_at Tcf4 transcription factor 4 867 3607 4.16 11.82 2.06 4.16 
0.0014
157 
706.37
5 
1393454_at Pcdh17 protocadherin 17 734 3600 4.90 11.81 2.29 4.90 
4.24E-
05 
23566.
955 
1388453_at Myadm 
myeloid-associated 
differentiation marker 555 3522 6.34 11.78 2.67 6.34 
6.27E-
05 
15944.
579 
1394907_at Synpo synaptopodin 89 3493 39.23 11.77 5.29 39.23 
0.0016
678 
599.57
5 
1371354_at Tnnc1 
troponin C type 1 
(Winslow, Swenberg et 
al.) 89 3467 39.15 11.76 5.29 39.15 
0.0003
325 
3007.4
03 
1376102_at Tmbim1 
transmembrane BAX 
inhibitor motif containing 
1 504 3333 6.62 11.70 2.73 6.62 
2.61E-
05 
38251.
027 
1391406_at Degs1 
delta(4)-desaturase, 
sphingolipid 1 439 3296 7.50 11.69 2.91 7.50 
0.0001
125 
8885.7
61 
1379713_at 
LOC102557
211 
uncharacterized 
LOC102557211 122 3256 26.69 11.67 4.74 26.69 
0.0003
357 
2978.6
00 
1372947_at Pls3 plastin 3 605 3241 5.36 11.66 2.42 5.36 
0.0001
756 
5695.0
05 
1372473_at Tjp1 tight junction protein 1 416 3206 7.70 11.65 2.94 7.70 
0.0008
439 
1185.0
23 
1373613_at Slc48a1 
solute carrier family 48 
(heme transporter), 
member 1 401 3175 7.92 11.63 2.98 7.92 
0.0012
297 
813.22
1 
1372587_at Emcn endomucin 515 3084 5.99 11.59 2.58 5.99 
1.86E-
05 
53845.
999 
1372064_at Cxcl16 
chemokine (C-X-C motif) 
ligand 16 575 3023 5.25 11.56 2.39 5.25 
0.0006
63 
1508.4
09 
1369153_at Nphs1 
nephrosis 1, congenital, 
Finnish type (nephrin) 82 2964 36.33 11.53 5.18 36.33 
1.45E-
06 
690711
.065 
1388831_at Slc9a3r2 
solute carrier family 9, 
subfamily A (NHE3, 
cation proton antiporter 
3), member 3 regulator 2 326 2892 8.86 11.50 3.15 8.86 
0.0013
201 
757.52
0 
1367800_at 
LOC100910
418 
tissue-type plasminogen 
activator-
like|plasminogen 
activator, tissue 237 2849 12.01 11.48 3.59 12.01 
8.42E-
05 
11882.
718 
1367563_at Sparc 
secreted protein, acidic, 
cysteine-rich 
(osteonectin) 692 2770 4.00 11.44 2.00 4.00 
0.0005
487 
1822.5
00 
1371430_at Dag1 
dystroglycan 1 
(dystrophin-associated 
glycoprotein 1) 550 2736 4.98 11.42 2.32 4.98 
0.0011
119 
899.37
3 
1371702_at Tspan7 tetraspanin 7 453 2577 5.69 11.33 2.51 5.69 
0.0001
904 
5253.0
99 
1390207_at Lats2 
large tumor suppressor 
kinase 2 555 2554 4.60 11.32 2.20 4.60 
0.0005
99 
1669.5
18 
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1395754_at Frem2 
Fras1 related 
extracellular matrix 
protein 2 226 2475 10.94 11.27 3.45 10.94 
0.0051
024 
195.98
7 
1395408_at Nostrin 
nitric oxide synthase 
trafficking 98 2471 25.29 11.27 4.66 25.29 
0.0004
495 
2224.8
57 
1387995_a
_at Ifitm3 
interferon induced 
transmembrane protein 
3 559 2457 4.40 11.26 2.14 4.40 
0.0082
016 
121.92
7 
1387122_at Plagl1 
pleiomorphic adenoma 
gene-like 1 540 2438 4.52 11.25 2.18 4.52 
0.0008
974 
1114.2
78 
1380544_at Foxp1 forkhead box P1 230 2365 10.27 11.21 3.36 10.27 
0.0077
722 
128.66
4 
1372585_at 
LOC100910
973 
uncharacterized 
LOC100910973 457 2315 5.07 11.18 2.34 5.07 
0.0050
478 
198.10
8 
1371356_at Tenc1 
tensin like C1 domain 
containing phosphatase 
(tensin 2) 448 2250 5.02 11.14 2.33 5.02 
0.0005
484 
1823.3
61 
1372564_at Ets2 
v-ets avian 
erythroblastosis virus E26 
oncogene homolog 2 418 2234 5.35 11.13 2.42 5.35 
0.0027
35 
365.62
6 
1387933_s
_at Podxl podocalyxin-like 172 2210 12.88 11.11 3.69 12.88 
0.0016
032 
623.76
0 
1376782_at Cdc14a cell division cycle 14A 417 2200 5.28 11.10 2.40 5.28 
0.0047
175 
211.97
7 
1367648_at Igfbp2 
insulin-like growth factor 
binding protein 2 63 2179 34.57 11.09 5.11 34.57 
0.0018
372 
544.30
4 
1369476_at Efnb1 ephrin B1 173 2178 12.56 11.09 3.65 12.56 
0.0035
968 
278.02
4 
1373403_at 
LOC100910
163|LOC68
4871 
uncharacterized 
LOC100910163|similar to 
Protein C8orf4 (Thyroid 
cancer protein 1) (TC-1) 534 2154 4.03 11.07 2.01 4.03 
8.49E-
07 
117836
7.516 
1368884_at Entpd1 
ectonucleoside 
triphosphate 
diphosphohydrolase 1 205 2140 10.45 11.06 3.39 10.45 
0.0002
764 
3617.7
27 
1368473_at Gja5 
gap junction protein, 
alpha 5 227 2060 9.09 11.01 3.18 9.09 
0.0012
216 
818.60
4 
1379443_at Hps3 
Hermansky-Pudlak 
syndrome 3 homolog 
(human) 385 2054 5.33 11.00 2.41 5.33 
0.0085
174 
117.40
7 
1388837_at Slc44a2 
solute carrier family 44 
(choline transporter), 
member 2 282 2000 7.10 10.97 2.83 7.10 
0.0043
618 
229.26
4 
1377286_at Gimap4 
GTPase, IMAP family 
member 4 161 1985 12.30 10.96 3.62 12.30 
0.0006
026 
1659.5
23 
1368901_at Thbd thrombomodulin 128 1979 15.51 10.95 3.96 15.51 
0.0006
995 
1429.5
78 
1386921_at Cpe carboxypeptidase E 232 1979 8.53 10.95 3.09 8.53 
2.47E-
05 
40439.
957 
1369793_a
_at Mcam 
melanoma cell adhesion 
molecule 361 1919 5.31 10.91 2.41 5.31 
0.0089
169 
112.14
6 
1395516_at Arglu1 
arginine and glutamate 
rich 1 441 1918 4.35 10.91 2.12 4.35 
0.0005
196 
1924.4
44 
1374630_at Clic3 
chloride intracellular 
channel 3 61 1879 30.85 10.88 4.95 30.85 
6.91E-
05 
14472.
947 
1373541_at Arhgef17 
Rho guanine nucleotide 
exchange factor (GEF) 17 254 1810 7.12 10.82 2.83 7.12 
0.0017
859 
559.95
4 
1389282_at Itga3 integrin, alpha 3 130 1802 13.82 10.82 3.79 13.82 
0.0006
072 
1646.8
67 
1369273_a
_at Npr3 
natriuretic peptide 
receptor 3 81 1801 22.31 10.81 4.48 22.31 
0.0073
782 
135.53
4 
1373357_at Foxd2 forkhead box D2 69 1794 25.89 10.81 4.69 25.89 
0.0014
121 
708.17
2 
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1388177_at Ddn dendrin 89 1775 19.87 10.79 4.31 19.87 
7.52E-
05 
13303.
948 
1376150_at S1pr3 
sphingosine-1-phosphate 
receptor 3 393 1755 4.46 10.78 2.16 4.46 
0.0001
634 
6120.4
75 
1374704_at Kdelc2 
KDEL (Lys-Asp-Glu-Leu) 
containing 2 227 1753 7.74 10.78 2.95 7.74 
0.0006
907 
1447.8
45 
1395078_at Sema3g 
sema domain, 
immunoglobulin domain 
(Ig), short basic domain, 
secreted, (semaphorin) 
3G 56 1598 28.65 10.64 4.84 28.65 
0.0006
905 
1448.1
82 
1370933_at Myo1e myosin IE 301 1575 5.24 10.62 2.39 5.24 
0.0195
424 51.171 
1395166_at Ehd2 EH-domain containing 2 331 1574 4.76 10.62 2.25 4.76 
2.61E-
05 
38321.
115 
1374403_at Efnb1 ephrin B1 210 1534 7.30 10.58 2.87 7.30 
0.0009
158 
1091.9
81 
1374774_at Ptpn14 
protein tyrosine 
phosphatase, non-
receptor type 14 234 1478 6.32 10.53 2.66 6.32 
0.0054
033 
185.07
3 
1393160_at Tbx3 T-box 3 105 1467 13.90 10.52 3.80 13.90 
0.0119
452 83.715 
1370893_at Acaca 
acetyl-CoA carboxylase 
alpha 306 1467 4.79 10.52 2.26 4.79 
0.0184
03 54.339 
1388920_at Bmp6 
bone morphogenetic 
protein 6 194 1454 7.51 10.51 2.91 7.51 
0.0033
929 
294.73
4 
1398275_at Mmp9 
matrix metallopeptidase 
9 48 1421 29.45 10.47 4.88 29.45 
2.23E-
05 
44803.
336 
1379742_at Sp100 SP100 nuclear antigen 282 1337 4.74 10.38 2.24 4.74 
0.0055
695 
179.54
9 
1369154_at Nphs1 
nephrosis 1, congenital, 
Finnish type (nephrin) 134 1336 10.00 10.38 3.32 10.00 
0.0001
086 
9211.6
72 
1387588_at Ehd3 EH-domain containing 3 268 1330 4.97 10.38 2.31 4.97 
0.0028
579 
349.91
1 
1367850_at Fcgr2a 
Fc fragment of IgG, low 
affinity IIa, receptor|low 
affinity immunoglobulin 
gamma Fc region 
receptor III-like|low 
affinity immunoglobulin 
gamma Fc region 
receptor III-like|low 
affinity immunoglobulin 
gamma Fc region 
receptor III-like|Fc 
gamma receptor II beta 281 1297 4.61 10.34 2.21 4.61 
0.0171
063 58.458 
1369949_at Bcam 
basal cell adhesion 
molecule (Lutheran 
blood group) 158 1293 8.19 10.34 3.03 8.19 
0.0103
792 96.346 
1370402_at Egfl7 
EGF-like-domain, 
multiple 7 317 1293 4.07 10.34 2.03 4.07 
0.0013
017 
768.21
5 
1391499_at 
LOC100909
676 
uncharacterized 
LOC100909676 70 1288 18.53 10.33 4.21 18.53 
0.0005
037 
1985.3
24 
1368513_at 
Enpep|LOC
100910501 
glutamyl 
aminopeptidase|glutamy
l aminopeptidase-like 249 1254 5.05 10.29 2.34 5.05 
0.0001
084 
9228.0
42 
1370406_a
_at Cd55 Cd55 molecule 86 1248 14.47 10.28 3.85 14.47 
0.0012
972 
770.88
0 
1383155_at Fam117b 
family with sequence 
similarity 117, member B 230 1242 5.39 10.28 2.43 5.39 
6.42E-
05 
15566.
282 
1379604_at Apol3 apolipoprotein L, 3 162 1229 7.59 10.26 2.92 7.59 
0.0021
724 
460.31
2 
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1393401_at Ecscr 
endothelial cell surface 
expressed chemotaxis 
and apoptosis regulator 68 1215 17.93 10.25 4.16 17.93 
0.0037
415 
267.27
1 
1373036_at Iqgap2 
IQ motif containing 
GTPase activating protein 
2 260 1214 4.67 10.25 2.22 4.67 
0.0001
047 
9554.0
94 
1389913_at Lrrfip1 
leucine rich repeat (in 
FLII) interacting protein 1 205 1210 5.90 10.24 2.56 5.90 
0.0009
574 
1044.5
27 
1390437_at Sema5a 
sema domain, seven 
thrombospondin repeats 
(type 1 and type 1-like), 
transmembrane domain 
(TM) and short 
cytoplasmic domain, 
(semaphorin) 5A 191 1199 6.28 10.23 2.65 6.28 
0.0018
761 
533.01
1 
1370287_a
_at Tpm1 tropomyosin 1, alpha 179 1189 6.64 10.21 2.73 6.64 
0.0030
244 
330.64
7 
1391435_at Pltp 
phospholipid transfer 
protein 107 1188 11.15 10.21 3.48 11.15 
0.0033
624 
297.40
4 
1390389_at Mertk 
c-mer proto-oncogene 
tyrosine kinase 114 1182 10.36 10.21 3.37 10.36 
0.0002
476 
4039.2
29 
1369651_at Thy1 Thy-1 cell surface antigen 109 1175 10.83 10.20 3.44 10.83 
0.0034
901 
286.52
7 
1388848_at Inf2 
inverted formin, FH2 and 
WH2 domain containing 100 1142 11.41 10.16 3.51 11.41 
0.0010
367 
964.63
4 
1384558_at Plac9 placenta-specific 9 61 1137 18.74 10.15 4.23 18.74 
0.0003
533 
2830.4
28 
1371627_at Amotl1 angiomotin-like 1 152 1135 7.47 10.15 2.90 7.47 
0.0004
716 
2120.5
68 
1387165_at Maf 
v-maf avian 
musculoaponeurotic 
fibrosarcoma oncogene 
homolog 275 1131 4.12 10.14 2.04 4.12 
0.0137
978 72.475 
1386282_x
_at Snrk SNF related kinase 223 1131 5.07 10.14 2.34 5.07 
0.0212
992 46.950 
1382732_at Lyve1 
lymphatic vessel 
endothelial hyaluronan 
receptor 1 156 1130 7.23 10.14 2.85 7.23 
2.47E-
05 
40479.
024 
1388763_at Cnn2 calponin 2 266 1119 4.21 10.13 2.07 4.21 
0.0003
467 
2884.6
86 
1377223_at Wt1 Wilms tumor 1 49 1119 22.86 10.13 4.51 22.86 
0.0016
841 
593.77
3 
1385354_at Itga8 integrin, alpha 8 136 1117 8.20 10.13 3.04 8.20 
0.0013
056 
765.94
3 
1387976_at Slc9a3r2 
solute carrier family 9, 
subfamily A (NHE3, 
cation proton antiporter 
3), member 3 regulator 2 178 1115 6.25 10.12 2.64 6.25 
0.0026
025 
384.24
9 
1390606_at Hhip 
Hedgehog-interacting 
protein 35 1102 31.31 10.11 4.97 31.31 
0.0017
23 
580.38
6 
1372583_at Tmtc1 
transmembrane and 
tetratricopeptide repeat 
containing 1 128 1065 8.34 10.06 3.06 8.34 
0.0001
293 
7734.3
39 
1389617_at Elk3 
ELK3, member of ETS 
oncogene family 176 1049 5.96 10.03 2.58 5.96 
0.0031
35 
318.97
5 
1395978_at Clec1a 
C-type lectin domain 
family 1, member A 121 1033 8.50 10.01 3.09 8.50 
0.0004
152 
2408.5
76 
1369968_at Ptn pleiotrophin 154 1031 6.68 10.01 2.74 6.68 
0.0004
269 
2342.2
80 
1371527_at Emp1 
epithelial membrane 
protein 1 196 1023 5.22 10.00 2.39 5.22 
0.0013
466 
742.59
2 
1376858_at Exoc3l2 
exocyst complex 
component 3-like 2 186 1021 5.50 10.00 2.46 5.50 
5.75E-
05 
17383.
458 
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1383372_at Ptafr 
platelet-activating factor 
receptor 158 1021 6.44 10.00 2.69 6.44 
2.40E-
06 
416325
.766 
1369779_at Myo1d myosin ID 234 1016 4.34 9.99 2.12 4.34 
0.0003
167 
3157.9
30 
1385226_at Kctd11 
potassium channel 
tetramerization domain 
containing 11 127 1015 7.97 9.99 2.99 7.97 
0.0254
865 39.236 
1383273_a
_at Pcbp3 poly(rC) binding protein 3 245 1002 4.08 9.97 2.03 4.08 
0.0656
498 15.232 
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Supplementary data Table 4: Gene list of Gene expression analysis from rat podocytes primary 
culture treated with PAN and cisplatin 
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1370912_at Hspa1a heat shock 70kD protein 1A 1 9.3672 1.8340 8.3946 
1368247_at Hspa1a|Hspa1b heat shock 70kD protein 
1A|heat shock 70kD protein 
1B (mapped) 
1 5.4542 1.4256 5.6690 
1373767_at Zfand2a zinc finger, AN1-type 
domain 2A 
1 3.2439 1.9577 2.8396 
1386321_s_at Trib3 tribbles pseudokinase 3 1 2.1687 1.3338 1.8518 
1369590_a_at Ddit3 DNA-damage inducible 
transcript 3 
1 1.4230 1.0692 2.0800 
1385620_at Hsph1 heat shock 105/110 protein 
1 
1 1.5590 1.0883 1.6830 
1395680_at Sh3gl1 SH3-domain GRB2-like 1 1 1.6718 1.1442 1.3394 
1394100_at Ffar2 free fatty acid receptor 2 1 1.6514 1.2473 1.0352 
1376504_at Bai1 brain-specific angiogenesis 
inhibitor 1 
1 1.2693 1.6322 1.0797 
1388898_at Hsph1 heat shock 105/110 protein 
1 
1 1.5595 1.0978 1.6016 
1387434_at Slc22a4 solute carrier family 22 
(organic cation/zwitterion 
transporter), member 4 
1 1.2432 1.2804 1.6011 
1390332_at Zfp692 zinc finger protein 692 1 1.5999 1.1073 -1.0315 
1378560_at Per2 period circadian clock 2 1 1.1268 1.5999 1.5254 
1370695_s_at Trib3 tribbles pseudokinase 3 1 1.5105 1.1495 1.4798 
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1370970_at Kcnj14 potassium inwardly-
rectifying channel, 
subfamily J, member 14 
1 1.1789 -1.0063 1.5091 
1377702_at Lpar6 lysophosphatidic acid 
receptor 6 
1 -1.1746 -1.0889 -1.5009 
1370842_at Bckdk branched chain ketoacid 
dehydrogenase kinase 
1 -1.1145 -1.5014 -1.1301 
1368109_at St3gal5 ST3 beta-galactoside alpha-
2,3-sialyltransferase 5 
1 -1.2052 -1.1150 -1.5135 
1388600_at Paqr8 progestin and adipoQ 
receptor family member VIII 
1 -1.1237 -1.0475 -1.5466 
1373288_at St5 suppression of 
tumorigenicity 5 
1 -1.1701 -1.0881 -1.5545 
1385969_at Adamts16 ADAM metallopeptidase 
with thrombospondin type 
1 motif, 16 
1 -1.0155 -1.0548 -1.6276 
1379026_at Rhbdl3 rhomboid, veinlet-like 3 
(Drosophila) 
1 1.0166 -1.2699 -1.6370 
1393762_at Kat2b K(lysine) acetyltransferase 
2B 
1 -1.5308 -1.2714 -1.6457 
1390931_at Adamts15 ADAM metallopeptidase 
with thrombospondin type 
1 motif, 15 
1 1.0200 1.0150 -1.7764 
1377336_at Sema3b sema domain, 
immunoglobulin domain 
(Ig), short basic domain, 
secreted, (semaphorin) 3B 
1 -1.4284 -1.0729 -1.7919 
1371286_at Plaur plasminogen activator, 
urokinase receptor 
1 -1.2973 -1.1181 -2.1228 
1392647_at Saal1 serum amyloid A-like 1 1 -1.4974 -1.3127 -2.2034 
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